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ABSTRACT 
 
Regulation of Epithelial-Mesenchymal Transition and DNA Damage Responses by 
Singleminded-2s.   
(August 2008) 
Brian Laffin, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. Weston W. Porter 
      
 
 
 Virtually all signaling pathways that play key roles in development such as the 
transfroming growth factor (TGF)-beta, notch, and wnt pathways also influence tumor 
formation, implying that cancer is in a sense development gone awry. Therefore, 
identification and elucidation of developmental pathways has great potential for 
generating new diagnostic tools and molecular therapy targets. Singleminded-2s 
(SIM2s), a splice variant of the basic helilx-loop-helix / PER-ARNT-SIM (bHLH/PAS) 
transcriptional repressor Singleminded-2, is lost or repressed in approximately 70% of 
human breast tumors and has a profound influence on normal mammary development. In 
order to gain a better understanding of the mechanisms by which SIM2s restricts 
malignant transformation and progression in breast cancer, we depleted SIM2 RNA in 
MCF-7 cells using a retroviral shRNA system and examined gene expression and 
functional abilities of the SIM2-depleted MCF-7 cells (SIM2i) relative to a control MCF 
line expressing a non-specific “scrambled” shRNA (SCR). Depletion of SIM2 resulted 
in an epithelial-mesenchymal transition (EMT)-like effect characterized by increased 
  iv
migration and invasion, altered morphology, and loss of epithelial markers concomitant 
with gain of mesenchymal markers. The root of this effect may be loss of SIM2-
mediated repression of the E-cadherin repressor slug, as SIM2 is able to bind and repress 
transcription from the slug promoter, and slug expression is dramatically elevated in 
SIM2i MCF-7 cells. Consistent with the previously established role of slug in resistance 
to various cancer therapies, SIM2i cells are resistant to the radiomimetic doxorubicin 
and appear to have elevated self-renewal capacity under certain conditions. Intriguingly, 
SIM2 protein levels are elevated by treatment with DNA damaging agents, and SIM2 
interacts with the p53 complex via co-regulation of specific p53- target gene such as 
p21/WAF1/CIP1. These results provide a plausible mechanism for the tumor suppressor 
activity of SIM2, and provide insight into a novel tumor suppressive transcriptional 
circuit that may have utility as a therapeutic target. 
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NOMENCLATURE 
 
AP-1   Activator protein-1 
AHR   Aryl hydrocarbon receptor 
ARNT   Aryl hydrocarbon receptor nuclear translocator 
bHLH   Basic helix-loop-helix 
C/EBPβ  CCAAT/enhancer binding protein, beta 
ChIP   Chromatin immunoprecipitation 
CME   Central midline element 
DMBA  7,12-dimethylbenz[a]anthracene 
DMEM  Dulbecco’s modified Eagle’s medium 
DOX   Doxorubicin 
DS   DS 
DSL   Delta/Serrate/lag-2 
E   Embryonic day 
EGF   Epidermal growth factor 
EGFR   Epidermal growth factor receptor 
EMT   Epithelial-mesenchymal transition 
ETS2   V-ets erythroblastosis virus E26 oncogene homolog 2 
HIF1-α  Hypoxia-inducible factor 1 alpha   
HIF2-α  Hypoxia-inducible factor 2 alpha 
HRE   Hypoxia response element 
  viii
IκB   Inhibitor of kappaB  
IKK    Inhibitor of kappaB kinase  
MAPK   Mitogen-activated protein kinase 
NFκB   Nuclear factor-kappaB 
NICD    Notch intracellular domain 
PAS   Per-Arnt-Sim 
PI3K   Phosphatidylinositol 3′-kinase 
SIM1   Single-minded 1 
SIM2   Single-minded 2 
SIM2s   Single-minded 2, short isoform 
TEB   Terminal end bud 
TGFβ   Transforming growth factor beta 
XRE   Xenobiotic response element 
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CHAPTER I 
INTRODUCTION 
 
Breast cancer is the second most common malignancy in women and the second 
leading cause of cancer death in women, with an estimated 178,480 new cases of invasive 
disease and 62,030 cases of in situ disease along with approximately 40,460 deaths from 
breast cancer in 2007 American Cancer Society.  Breast cancer retains its position as the 
second most common malignancy despite introduction of improved estimation methods, 
which have resulted in new case figures dramatically lower than the 2005 estimate.  Early 
detection and new treatments have significantly improved the mortality rate of breast 
cancer patients, however, it is becoming increasingly clear that many current treatments 
simply diminish the bulk of the tumor without destroying the so-called tumor initiating 
cells the that are primarily responsible for tumor growth, invasion, angiogenesis, 
metastasis, and recurrence (1-5).  This makes understanding the developmental pathways 
that are hijacked or dismantled by tumor-initiating cells to acquire de-differentiated stem 
cell-like properties critical to development of therapies that can truly destroy tumors. 
Understanding how these pathways function in normal development and the adult 
organism is also of great importance for creating targeted therapies that will cause the 
least of amount of suffering possible for the patient while delivering the maximum 
therapeutic effect.  
 
This dissertation follows the style of Cancer Research. 
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1.1 Normal mammary gland development   
The first morphological descriptions of mammary gland development were 
undertaken in the 1900s, proceeding through investigations of tissue interaction in the 
mammary placodes and young virgins glands in the 1960s up to the molecular studies of 
the present day (6, 7).  The mammary gland has evolved in egg-laying synapsids during 
the Pennsylvanian epoch as a means of hydrating and nourishing thin-shelled eggs that 
would otherwise dry out (8, 9).  In mammals, the ectoderm-derived mammary gland 
functions primarily to provide nutrients to offspring, but also confers immune protection 
through transfer of maternal antibodies to the young. The mammary gland develops in 
three distinct stages (Fig. 1), embryonic, pubertal, and adult, the latter two of which are 
under the control of circulating hormones and growth factors.  
 
 The embryonic stage of mouse mammary development begins with the formation 
of mammary placodes along the so-called “milk line”, which is defined by expression of 
Wnt10b (10). In female mice, the epithelium then condenses into bulb-like mammary 
buds at distinct locations on the milk line, while in male mice androgen acting on the 
mammary mesenchyme causes bud regression (11-13). The bulb elongates under control 
of interaction between parathyroid hormone related protein (PTHrP) and bone 
morphogenetic protein (BMP) signaling, invades into the fat pad beneath the skin, and 
forms a nipple with a lumen that opens to the skin (14). This PTHrP – BMP interaction 
also functions to suppress hair follicle development in the vicinity of the nascent gland, 
via induction of MSX2 (14). Invasion into the fat pad is led by dense epithelial structures 
called terminal end buds, or TEBs. TEBs, which appear at the tips of elongating 
mammary ducts in young virgin animals, consist of multiple layers of body cells 
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surrounded by a cap cell layer. Proliferation occurs exclusively in the cap cell layer, 
which expresses enzymes that facilitate fat pad invasion, leaving the elongating duct 
behind (15-17). Interaction between the TEB and the surrounding stroma guides invasion 
into the fat pad, and may also instruct clefting events that result in bifurcation ands 
trifurcations that in concert with side branching events give rise to the ductal tree.  
  
 
 
 
 This process, termed branching morphogenesis, occurs in many organs such as 
the lungs and kidneys (18, 19), suggesting that a conserved branching transcriptional 
module exists and is heavily involved in the execution of all developmental branching 
L L
L L
Early Virgin Adult Virgin 
Pregnant 
Figure 1 Post-natal mammary ductal tree morphology. TEB outgrowth in early virgin glands along with 
side branching events results in a ductal tree that reaches to the end of  the fat pad in the adult virgin. 
Hormonal changes during pregnancy initiate the formation of lobuloalveolar units for milk production, 
which by the time of lactation have almost completely filled the fat pad. After pups are weaned, the 
gland returns to the pre-pregnant state via the process of involution. 
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processes. This branching module orchestrates expression of the tissue remodeling 
factors such as matrix metalloproteases (MMPs) that drive ductal extension and 
branching (15-17). Broad inhibition of MMPs does not block initial formation of lateral 
branches, but ductal extension appears to require MMP activity (15). MMP2 null mice 
display impaired ductal extension as expected (15), and extensive lateral branching in 
MMP2-/- glands suggests that MMP2 supresses lateral branching. Surprisingly, these 
effects appear to be mediated through effects on cell survival and proliferation within the 
TEB, despite localization of the MMP2 activator MMP14 at the tips of TEBs (15). 
MMP3 acts antagonistically to MMP2 and promotes lateral branching, as MMP3 null 
mice had greatly reduced numbers of branch points (15). However, the number of TEBs 
and duct length in MMP3 null mice was unchanged, implying that MMP3 is not involved 
in TEB invasion or bifurcation (15). Other factors can compensate for MMP3, as MMP3 
null mice eventually catch up to wild type controls in ductal development (ref). 
Additionally, there is evidence that as the tree penetrates into the fat pad, morphogen 
gradients created by the geometry of the extending tree have a strong influence on branch 
point selection and the frequency of side branching (20). Growth of the mammary ductal 
tree slows or ceases altogether with the reaching of the end of the fat pad and puberty-
associated rises in estrogen. Although elevated estrogen levels contribute to stopping 
ductal tree outgrowth, estrogen signaling is critical to virgin mammary development, as 
estrogen receptor-α (ERα) null mice lack TEBs and are deficient in ductal invasion into 
the fat pad (21, 22).  This phenotype appears to be due in part to a lack of ERα -driven 
expression of the estrogen-responsive EGFR ligand amphiregulin, as the ductal 
phenotype of ERα, amphiregulin, and EGFR null mice are highly similar (23-26). 
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Amphiregulin function requires proteolytic release from the cell membrane by 
ADAM17/TACE, consistent with the phenotypic similarity of ADAM17-/- mice to ERα, 
amphiregulin, and EGFR null mice (27). Consistent with all of these observations, lack of 
mammary gland development in ovariectomized mice can be rescued by EGF or TGFα 
pellets, but not by insulin or albumin containing pellets (28). This demonstrates that 
circulating hormones exert their effects by driving expression of paracrine-acting growth 
factors. Apoptosis within the body cells left behind by invading TEBs has been proposed 
as the mechanism by which lumen formation occurs, and indeed, deletion of the pro-
apoptotic protein Bim delays lumen formation significantly (29, 30). The ducts in Bim 
null mice eventually form lumens, demonstrating that functionally redundant apoptotic 
processes ensure eventual lumen formation. After puberty, estrogen cycling gives rise to 
waves of side-branch formation and apoptotic dieback, mimicking on a small scale the 
dramatic changes that occur during pregnancy, lactation, and involution. The amount of 
this estrous-related side branching that occurs varies widely between mouse strains, but 
can be quite extensive. 
 
 During pregnancy, the hormones progesterone and prolactin drive the gene 
expression and morphologic changes necessary to effect lactation, namely the formation 
and differentiation of alveolar subunits, where milk production occurs. Progesterone, 
through the action of its receptor, is a prime mover in the formation of side branches and 
alveolar units during pregnancy (31). Progesterone also acts in concert with prolactin 
(PRL) signaling through the prolactin receptor to promote differentiation of the alveolar 
cells, which produce the large quantities milk needed during lactation (31, 32). During 
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lactation, PRL-induced phosphorylation of STAT-5 and subsequent milk protein mRNA 
transcription interact with translational control mechanisms to generate elevated amounts 
of caseins and other milk proteins, resulting in production of up to 5 mL of milk per day 
(33-39).  As the offspring grow and are weaned, milk accumulation triggers involution, a 
cell death and fatty tissue regeneration process that returns the gland to its pre-pregnant 
state. Involution occurs in two distinct stages which are defined by the point at which 
suckling is no longer able to reverse the involution process (40). The first, reversible 
stage lasts roughly 48 hrs and characterized by decreased expression of pro-survival 
proteins and increased expression of pro-apoptotic proteins (41). The second, irreversible 
stage starts with clearance of apoptotic cells and excess milk by the epithelium followed 
by macrophage and MMP-mediated tissue remodeling that reverses the pregnancy-
associated epithelial expansion as the animal resumes estrous cycling (40, 42). In addition 
to the radical changes in the epithelium of the mammary gland during pregnancy and 
lactation, the extracellular matrix (ECM) simultaneously undergoes dynamic changes that 
contribute to mammary gland function and affect the phenotype of pregnancy-associated 
breast cancer (43, 44). 
 
 
1.2 The history of breast cancer and chemotherapy 
 
Breast cancer was one of the first tumors to be described in ancient medical 
writings. The Edwin Smith Papyrus, which is the earliest known medical writing of any 
kind, was written around 1600 BC and describes 8 cases of breast ulcers or tumors in 
humans, one of whom was a man. While Egyptian doctors were sometimes able to 
remove the tumors by cauterizing them with an instrument called a “fire drill”, the 
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disease was essentially incurable at that time. This state of knowledge and care for breast 
cancer patients remained largely unchanged for centuries, until the work of Jean Louis 
Petit and Benjamin Bell in the early 18th century. Bell and Petit were the first to advocate 
removal of surrounding tissue, lymph nodes, and muscle in addition to the tumor mass 
itself to combat recurrence and metastasis. Their work was continued and expanded upon 
by Dr. William Halsted, who performed the first complete mastectomy in 1882.  The 
procedure that bears his name, the Halsted radical mastectomy, is still performed to this 
day. Breast cancer treatment took its next major step forward in 1946. The port-mortem 
observation of lymphoid and myeloid depletion in persons exposed to nitrogen mustard 
gas led to seminal work by Goodman, Gilman, and Linskog which demonstrated that 
lymphomas could be shrunk by injection of nitrogen mustard compounds and established 
the feasibility of cancer chemotherapy (45, 46). In 1952 the first major contribution to 
improving the mental well being of breast cancer patients and survivors was made by 
Terese Lasser when she founded the Reach to Recovery program (47). Reach to 
Recovery employs trained volunteers, many of whom are mastectomy patients and cancer 
survivors, to provide emotional support and guidance to breast cancer patients and help 
them to maintain their feeling of personal dignity. This program and others like it have 
raised awareness of the devastating impact cancer has on a patient’s entire life and had a 
profound positive impact on the quality of life had by breast cancer patients and 
survivors. 
 
Additional steps forward in cancer therapy such as the discovery of the anticancer 
activity of antifolates, 6-mercaptopurine, and vinca alkaloids led congress to establish the 
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National Cancer Chemotherapy Service Center (NCCSC) at the National Cancer Institute 
(NCI) in 1955. The NCCSC was the first federal program promoting cancer drug 
discovery, and generated numerous animal models and cell lines in its pioneering drug 
development efforts, leading to the relatively rapid development of additional 
chemotherapeutic drugs such as the taxanes in 1964 and camptothecins in 1966. Cisplatin 
and Tamoxifen were also discovered during this time, but were not approved for use in 
human cancers until the 1970s. 1965 saw a major paradigm shift in cancer chemotherapy: 
contemplating the problem of mutation-induced drug resistance in tumors, James 
Holland, Emil Freireich, and Emil Frei extrapolated the multi-drug treatment regimens 
used to treat tuberculosis to treatment of leukemias by simultaneously administering 
methotrexate, vincristine, 6-mercaptopurine (6-MP) and prednisone— together referred 
to as the POMP regimen — and induced long-term remissions in children with acute 
lymphoblastic leukaemia (ALL).  Bernard Fisher and Gianni Bonadonna independently 
followed this and additional work by Dr. Frei in osteosarcomas by showing that adjuvant 
chemotherapy after complete surgical resection of breast tumours significantly extended 
survival — particularly in more advanced cancer (48, 49).   
 
From the 1970s to the 1990s, several other classes of drugs were developed such 
as the anthracyclines, nitrosoureas, and epipodophyllotoxins, as well as supporting 
therapies such as anti-nausea drugs. With the advent of genomics, proteomics, and other 
high-throughput techniques, knowledge of tumor signaling networks has exploded to the 
point that therapies that target specific weak points of tumors with greatly reduced 
damage to normal tissue are now possible. Examples of this are tyrosine kinase inhibitors 
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such as imatinib, which specifically targets the oncogenic fusion protein BCR-ABL, and 
humanized antibodies such trastuzumab, which inactivates the product of the HER2/neu 
oncogene in breast tumors (50, 51). The promise of these targeted therapies makes 
understanding tumor signaling networks of the utmost importance, so as to elucidate new 
targets and create the most possibilities for combination therapies in the infinitely 
heterogeneous tumor signaling networks encountered in patients. 
 
 
1.3 Types and subtypes of breast cancer 
 
 Breast cancer is a remarkably heterogeneous disease, with well over 50 types and 
subtypes of invasive disease currently recognized by the World Health Organization (52), 
a summary of which appears in Table 1(53-102) (103). Invasive ductal carcinomas 
represent the vast majority of breast tumors (52). While these tumors fall into the same 
category histologically, they are quite variable in clinical behavior, underscoring that 
these tumors cannot be broadly treated in the same way as might be warranted in rarer 
subtypes that have a more uniform set of genetic abnormalities. Groundbreaking work by 
Perou et al (104) and Sorlie et al (105) has provided a new approach to the problem posed 
by the morphologic similarity and behavioral heterogeneity of invasive ductal 
carcinomas. These studies demonstrated that gene expression profiling could sort 
invasive ductal carcinomas into 5-6 molecular subtypes - luminal A, luminal B, luminal 
C, normal breast-like, HER2 overexpressing, and basal-like – and that these groupings 
had significant predictive value for patient outcome. Luminal subtype may be viewed as a 
subset of luminal B tumors. Abbreviated molecular definitions of these subtypes and their 
relative prognosis is presented in table 2. 
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Table 1. Types and subtypes of invasive breast carcinomas. 
Type / Subtype 
Fr
eq
ue
nc
y 
 
Pr
og
no
si
s Description / characteristics 
Invasive ductal carcinoma (not 
otherwise specified) 
35-50% __ Generally ER-positive, Epithelioid 
Basal-like carcinoma 7-20% Poor Expression of high-molecular weight cytokeratins 5, 14 
and 17, Triple negative (ER, PR, p53) 
Mixed type carcinoma <1% Varies  Varies widely 
Pleomorphic carcinoma <1% Poor Frequent E-cadherin gene inactivation / LOH 
Carcinoma with osteoclastic 
giant cells 
<1% Good Osteoclastic giant cells present in stroma surrounding 
tumor  
Carcinoma with 
choriocarcinomatous features 
<1% Poor Elevated human chorionic gonadotropin-β expression, 
presence of multinucleated syncytiotrophoblast-like giant 
cells 
Invasive lobular carcinoma 10% Similar Small, “lens-like” nuclei, mucin-filled acini. Rows of 
cells sandwiched between collagen fascicles, poorly 
defined margins 
Tubular carcinoma 5% Good Highly differentiated, Low recurrence rate, low potential 
for metastasis, Generally ER positive 
Invasive cribriform carcinoma <1% Good Mucin positive, laminin negative cystic appearance. 
Luminal epithelial ultrastructural appearance. 
Medullary carcinoma  / 
Atypical medullary carcinoma 
6% Good Predominant syncytial growth pattern, featuring broad 
anastamosing sheets, microscopically complete 
circumscription, marked mononuclear stromal infiltrate, 
nuclear grade II or III. 
Mucinous carcinoma <5% Good Monomorphic ductal epithelial tumor cells “floating” in 
abundant background mucin pool, comprising more than 
90% of tumor. Low rate of metastatis, generally hormone 
receptor positive. 
Cystadenocarcinoma and 
columnar cell mucinous 
carcinoma 
<1% Good Predominantly tall, columnar mucinous epithelium. 
Presence of both intracellular and extracellular mucin 
Signet ring cell carcinoma <1% Poor Abundant intracellular mucin. Metastasis to the 
peritoneum, gastrointestinal tract, lung, and gynecologic 
organs. 
Neuroendocrine 
tumors  
 
<1% Varies Positive IHC for neuroendocrine markers. Small cell / oat 
cell carcinoma is the most agressive type. 
Invasive papillary carcinoma <1% Good Fibrovascular stromal core lined by epithelial and 
myoepithelial cells, attached to the wall of the duct and 
extending into the duct lumen 
Invasive micropapillary 
carcinoma 
<1% Poor Micropapillary epithelial architecture surrounded by 
lymphatic duct–like empty space. Aggressive behavior 
with frequent lymph node metastasis 
Apocrine carcinoma <1% Good ER, PR negative. Elevated expression of Androgen 
Receptor, psoriasin, S100A9, and p53. Low proliferative 
index.  
Metaplastic carcinomas <1% Poor Tumor cells display differentiation along multiple 
lineages. Generally aggressive clinical course, 
haematogenous metastasis pattern (lung and bone). 
Squamous cell carcinoma <1% Poor Presence of cells with squamous differentiation forming a 
keratinizing tissue, frequent lymph node metastasis, rapid 
growth 
All WHO-recognized histological types and subtypes for which there is sufficient published data to make 
statements about prognosis are shown. Prognosis shown is relative to not otherwise listed invasive ductal 
carcinomas.  
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Table 1, Continued. 
Type / Subtype 
Fr
eq
ue
nc
y 
 
Pr
og
no
si
s 
Description / characteristics 
Adenosquamous carcinoma 
 
<1% Similar Combination of glandular and squamous 
differentiation 
Mucoepidermoid carcinoma <1% Good Nesting pattern with multiple well-circumscribed 
squamous nests containing numerous clear cells. 
Prominent mucin-secreting component frequently 
present. Myoepithelial differentiation common.  
Mixed 
epithelial/mesenchymal 
metaplastic carcinomas 
<1% Poor Tumor cells display epithelial (carcinoma) and 
mesenchymal (sarcoma) differentiation. Generally 
agrgressive clinical course. 
Secretory carcinoma  
 
<1% Good Frequent presence of oncogenic ETV6-NTRK3 
fusion kinase. Most common in children.  
 Glycogen-rich clear cell 
carcinoma  
<1% Poor Finely granular eosinophilic cytoplasm or foamy to 
clear cytoplasm with well-defined cytoplasmic 
membranes, moderate to marked nuclear 
pleomorphism with prominent nucleoli 
Inflammatory carcinoma <10% Poor Presence of skin erythema and oedema. Rapidly 
growing tumors that are highly angiogenic, angio-
invasive,  numerous tumour emboli filling the 
dermal lymphatics causing inflammatory signs 
Myofibroblastoma <1% Good Densely packed large cells with a solid or 
trabecular growth pattern, focally arranged in nests,  
with abundant eosinophilic glassy cytoplasm and 
sharp cellular borders. Large and round nuclei, 
prominent nucleoli. P63 and vimentin positive. 
Inflammatory 
myofibroblastic tumor 
<1% Good Large cohesive sheets of histiocytes intermingled 
with clusters of spindle cells and mixed 
inflammatory cells. Lack of granulomas and ductal 
epithelial cells.  
Granular cell tumor <1% Good Granular cytoplasm. Fat necrosis, duct ectasia. 
Neurofibroma <1% Good Schwann cell origin. Composed of spindle cells 
with thin, often wavy nuclei. S100 positive, 
generally well-circumscribed.  
Schwannoma <1% Good S100 positive. Compact and spongy biphasic 
pattern, nuclear palisading, interlacing bundles of 
numerous elongated spindle shaped cells.  
Angiosarcoma <1% Poor Rapid growth. Malignant endothelial cells lining 
vascular channels are flat, and most nuclei are pale 
and small. Contains anastomosing vascular 
channels that surround and invade lobules.  
Liposarcoma <1% Variable Mature adipocytic proliferation, variable cell size, 
focal nuclear atypia of adipocytes and stromal cells. 
Osteosarcoma <1% Poor Osteoid production present. Broad eosinophilic 
seams were that may display mature bone 
formation. Frequent mitoses, early recurrence, 
haematogenous metastasis pattern (lung and bone). 
Leiomysarcoma <1% Similar Pleomorphic spindle cells,  hyperchromatism and 
elongated nuclei, eosinophilic cytoplasm, large 
nucleoli and numerous mitoses.  
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 In addition to their prognostic value, these classifications have implications for 
targeted therapies that will grow more important as understanding of tumor signaling 
pathways increases. Indeed, larger, more refined gene expression profiling studies 
centered around analysis of kinase gene expression can not only differentiate the subtypes 
previously described, but predict prognosis within the luminal A subtype (106). Many of 
these kinases, which were selected in an unbiased fashion for their ability to discriminate 
between the subtypes, are already therapeutic targets under investigation while others are 
potential targets.  
Table 2. Molecular subtypes of invasive ductal carcinoma. 
 
 
 
 
 
IDC subtype: Highly expressed 
genes: 
Weakly expressed 
genes: 
Average relative 
prognosis 
Normal breast-like Adipose tissue genes 
Basal epithelial genes 
Luminal epithelial genes Good 
Luminal A ERα 
Gata-3 
TFF3 
Keratin 8/18 
Luminal epithelial genes 
Basal epithelial genes 
Non-epithelial genes 
Best 
Luminal B Luminal epithelial genes ER cluster (moderate 
expression) 
Average 
Luminal C Luminal epithelial genes 
Subset of basal 
epithelial genes of 
unknown function 
ER cluster (moderate 
expression) 
Poor 
Basal-like Keratin 5 
Keratin 17 
FABP7 
Laminin 
ER cluster 
PR 
ERBB2 cluster 
Worst  
ERBB2+ ERBB2 
Others in ERBB2 
amplicon 
ER cluster Poor 
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1.4 Basal-like carcinomas 
 
Basal-like carcinomas are a subset of invasive ductal carcinomas that consistently 
have the poorest prognosis of all breast carcinomas whether grouped by histological 
appearance or molecular signature (104, 106-108). Basal-like carcinomas are also more 
aggressively metastatic than other invasive ductal carcinomas (109, 110). While recent 
studies have provided a fairly robust molecular definition for basal-like carcinomas, 
tumors displaying basal / myoepithelial differentiation were first described in the 1970s 
(111, 112). The basal phenotype is defined histologically by pushing margins, frequent 
central necrosis and lymphatic infiltrate, expression of high molecular weight keratins 
such as 5, 14 and 17, overexpression of EGFR / HER1, and frequently triple negative 
status for ER, PR, and ERBB2 / HER2 (113, 114).  On the molecular level, basal-like 
breast carcinomas frequently feature inactivation of the Rb tumor suppressor pathway, 
up-regulation of slug and other EMT-like changes (113-117). These abnormalities are 
frequently present in the in situ lesion (118-120), and may explain why basal-like 
carcinomas are highly sensitive to some treatments despite their poor prognosis (121, 
122). It has been proposed that basal-like carcinoma may have a more stem-cell-like 
phenotype, due to the significant overlap in their respective gene expression profiles 
(114, 123, 124). However, there is no published evidence that basal-like carcinomas have 
functionally greater stem cell capacity than luminal tumors, and the basal phenotype has 
an inverse correlation with some stem cell markers (108). Basal-like tumors have a more 
consistent pheontype in terms of metaplastic EMT-like elements. While the relevance of 
strictly-defined EMT to human breast carcinogenesis remains controversial (125), 
evidence is mounting that transient EMTs or EMT-like events are real phenomena that 
  14
are associated with metastasis, invasion, disease progression (114, 117, 126-132). These 
findings challenge assumptions made about the biology of basal-like carcinomas, and 
demonstrate the need for additional study into their molecular origins to develop targeted 
therapies and animal models for basal-like tumors, which are thus far confined to BRCA1 
models (133, 134).  
 
1.5 Epithelial-mesenchymal transition 
The importance of epithelial-mesenchymal transitions in embryonic development 
has been appreciated since work done in the laboratory of Elizabeth Hay in 1967 (135), 
when the role of EMT in gastrulation was established. Since that time, multiple studies 
have revealed a crucial role for EMT in the patterning of multiple mature and embryonic 
tissues including the heart, palate, and neural crest (136-139). During gastrulation, 
epiblast cells ingressing through the primitive groove undergo EMT and migrate into the 
blastocoel to form the mesoderm (140), until Noggin-mediated suppression of BMP 
signaling halts gastrulation (138). Blockage of EMT via disruption of BMP signaling 
leads to failure in either mesoderm or neural crest formation (141-143), demonstrating 
the centrality of EMT to these processes. During heart development, endocardial cushion 
mesenchyme formation occurs via EMT in cells residing in the atrioventicular (AV) 
canal, which invade into the underlying cardiac jelly and form the septal and valvular 
primordia via process dependent upon cross talk between the TGF-beta and Notch 
pathways (144-149). TGF-beta3 induced EMT is necessary for palate fusion, and 
involves induction of a LEF1-Smad2-Smad4 transcriptional complex that represses E-
cadherin and up-regulates vimentin and fibronectin in a beta-catenin independent fashion 
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(137, 150-153).  A central feature of EMT during gastrulation and other developmental 
events, as well as in pathological EMTs, is loss or suppression of E-cadherin and other 
epithelial adhesion molecules (127-130, 137, 139, 154-158) and acquisition of 
mesenchymal markers such as vimentin and N-cadherin (131, 159-162). These gene 
expression changes have functional consequences as in the case of cadherins, which have 
different adhesion strengths that can affect invasion and metastasis (163). 
 
 EMT is thought to be associated with the most aggressive cancers (117), and is 
likely to be more heterogenous in manifestation than EMTs in developmental settings, 
leading to the proposal that EMT-like events in tumor cells generate “metastable” cells 
that are an abnormal blending of epithelial and mesenchymal phenoypes and 
transcriptomes (164). This hypothesis is supported by the involvement of EMT-related 
factors in the metastasis of epithelioid cancers (126, 127, 162, 165-170), the similarity in 
phenotype of metastatic nodules to the parent tumor (171), and the dynamic EMT-MET 
processes known to be involved in bladder and colorectal cancer metastasis (172-175). 
These observations suggest that metastatic cells must shed enough of their epithelial 
nature to escape their tissue of origin, but retain the abilty to become epithelioid once 
again to facilitate extravasation and survival in the new tissue.  
 
Transcriptional control of EMT is complex, and in developmental settings 
typically begins with receipt of local molecular signals such as TGF-beta receptor ligands 
(141-143, 147) Wnts (176, 177), FGFs (178-181), and Notch ligands (149). TGF-beta 
and BMP signaling results both in broad chromatin remodeling via HMGA2 (182, 183) 
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and the assembly of numerous transcriptional complexes on pro-EMT gene promoter 
regions. These complexes include, but are not limited to Smad/LEF, Ets1, FoxC2, and 
MRTF-containing complexes, which drive expression of genes that suppress E-cadherin 
and other epithelial proteins while upregulating those associated with mesenchyme (137, 
152, 184-187). The list of E-cadherin repressors is long and includes Snail family 
members, Twist, Zeb proteins, EZH2, and E47 proteins, as well as many others, which 
are thought to act in concert in vivo to effect E-cadherin repression (127-129, 161, 182, 
188). One or more of these proteins are the eventual targets of all EMT-promoting 
signaling pathways. 
 
1.6 Transforming growth factor (TGF)-beta signaling 
TGF-β signaling (Fig. 2) begins with the synthesis of one of 30 or more TGF-β  
superfamily preprotein dimers, all of which must be proteolytically processed to be 
secreted (189). The TGF-β superfamily includes bone morphogenetic proteins (BMPs), 
TGF-β s, activin beta-chains, growth and differentiation factors (GDFs), and the protein 
nodal of which are typically secreted as homodimers, although some members can form 
heterodimers (190, 191). While most TGF-β superfamily members can be proteolytically 
processed after secretion, only GDF8, GDF11, and the TGF-β s require post-secretion 
processing to initiate signal transduction, which is performed by proteases such as BMP1, 
MMP2, MMP14, plasmin, or elastase (192-195). TGF-β s are secreted in a form known 
as the large latent complex, in which TGF-β  and its prodomain are bound by latent TGF-
β  binding proteins (LTBPs) and subsequently targeted to the ECM (193). After secretion 
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and in some cases proteolytic release of the mature, active ligand, TGF-β superfamily 
members bind their cognate receptors and induce formation of heterotetrameric  
 
Figure 2. TGF-β - SMAD signaling. TGF-β in its latent form is proteolytically cleaved and released for receptor binding by one of 
several proteases, and can be sequestered by ligand binding antagonists such as Noggin. Receptor-bound TGF-β triggers 
clustering and auto-phosphorylation of type I and type II TGF-β receptors, which phosphorylate and activate R-SMADs causing 
interaction with SMAD4 and nuclear translocation. Activate SMAD complexes displace the Ski/SnoN repressors, which are 
targeted to the prpteasome by the ubiquitin ligase Arkadia. The SMAD complex then recruits co-regulatory proteins such as 
SWI/SNF, p300, and CBP to effect target gene activation and repression. I-SMADs inhibit the TGF-β at multiple points, 
including blocking association of R-SMADs with active TGF-β receptors and target gene promoters, promotion of receptor de-
phosphorylation via recruitment of phosphatases, and targeting of active R-SMADs and receptors for degradation via the 
ubiquitin ligase SMURF. 
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complexes that then activate through autophosphorylation (196-198). These tetrameric 
complexes form from preexisting dimers of type I and type II TGF-β receptors, 
whereupon the constitutively active type II receptor dimer activates the type I receptor 
via phosphorylation (197, 198). TGF-β pathway activation can be stifled at this level by 
ligand-sequestering antagonists such as Chordin, Noggin, and Cerebus, which can either 
modulate the TGF-β signal strength or block it altogether. Activated receptor complexes 
recruit and activate members of the SMAD family of transcription factors (SMADs 1, 2, 
3, 5 and 8), which upon phosphorylation by the receptor complex are able to interact with 
SMAD4, the common binding partner of all receptor-regulated SMADs. Individual 
SMADs are recruited by specific type I TGF-β receptors; SMADs 1, 5, and 8 are 
phosphorylated by ALK1, 2, 3, and 6, while SMADs 2 and 3 are phosphorylated by 
ALK4, 5, and 7. SMAD complexes can act as transcriptional activators or repressors, 
depending upon phosphorylations and other modifications to SMADs that determine 
which proteins are recruited to target promoters. All SMADs with the exception of 
SMAD2 directly bind DNA, but are unable to recruit the basal transcriptional machinery, 
and act via chromatin remodeling enzymes such as SWI-SNF, p300, and CBP. In the 
absence of TGF-β pathway activation, SMAD response elements are often occupied by 
the transcriptional repressors SKI and SNON, which are rapidly degraded by the 
ubiquitin ligase Arkadia to allow for SMAD binding. 
 
In addition to the receptor associated SMADs and the co-SMAD, SMAD4, the 
inhibitory SMADS (I-SMADs) SMAD6 and SMAD7 provide feedback inhibition for 
TGF-β signaling. I-SMADs are induced by R-SMAD transcriptional activity and 
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attenuate TGF-β pathway activation through several mechanisms such as competition 
with R-SMADs for receptor binding, recruitment of SMURF ubiquitin ligases to 
activated TGF-β  receptors resulting in their degreadation, recruitment of phosphatases to 
active receptors causing their deactivation, and competition R-SMADs for binding to 
SMAD response elements in target promoters.  In addition to targeting genes involved in 
EMT such as E-cadherin and Vimentin, TGF-β receptor stimulation in untransformed 
cells elicits cell cycle arrest via SMAD/Sp mediated induction p15(Ink4b)(199, 200).  
This cytostatic induction of p15 is mediated by the transcription factor C/EBP-β and is 
required for the tumor suppressive effects of intact TGF-β pathway function (201, 202).  
 
1.7 The Wnt / β-catenin pathway 
 Wnt glycoproteins are the ligands for Frizzled receptor complexes, which consist 
of frizzled receptors and low density lipoprotein receptors. While Wnt/Frizzled signal 
transduction (Fig. 3) has numerous downstream effectors that contribute to EMT, the 
majority of its output proceeds through either the canonical (β-catenin) or planar cell 
polarity (PCP) pathway.  β-catenin normally resides at cell-cell junctions in a dynamic 
complex with other catenins and cadherins. When β-catenin is freed from these 
membrane-associated complexes, it ordinarily resides in a cytoplasmic pool that is 
targeted for destruction by a complex containing the scaffolding protein Axin and the 
Adenomatous polyposis coli (APC) tumor suppressor (203). Upon receipt of Wnt signals, 
β-catenin residing in this pool is stabilized by a mechanism that is poorly understood but 
appears to involve all 3 human homologs of the drosophila protein dishevelled in non-
overlapping roles (204).  
  20
 
 
 
 
Figure 3. Wnt-frizzled signaling. Engagement of the Wnt ligand by Frizzled receptors results in stabilization of cytoplasmic β-
catenin, which is a potent co-activator of LEF/TCF transcription factors. β-catenin normally exists in dynamic membrane -bound 
complexes with other catenins and cadherins, with some exiting to form a cytoplasmic pool that is targeted for proteosomal 
degradation by the Axin / APC / GSK-3β complex, which phosphorylates β-catenin priming it for ubiquitination. p68 RNA 
helicase promotes β-catenin stabilization by blocking this phosphorylation event. Wnt/Frizzled signaling also acts in β-catenin-
independent signaling modes such as through promotion of PKC-mediated phosphorylation and activation of Snail. 
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 The RNA helicase p68, which blocks phosphorylation of β-catenin in response to 
PDGF to promote EMT, may also play a role in Wnt-induced EMT or similar proteins 
may act in the fashion or p68 (205). Stabilized β-catenin translocates to the nucleus, 
where it acts as a potent co-activator for the LEF/ TCF family of transcription factors, 
leading to EMT (206-210). Wnt signaling can also lead to EMT through β-catenin-
independent pathways. Wnt5A induces EMT via PKC-dependent induction of Snail, even 
in the presence of dominant-negative TCF4, demonstrating that Wnt signaling promotes 
EMT via several pathways besides β-catenin (211). Similar to the action of the BMP 
antagonist Noggin in the TGF-β pathway, secreted inhibitors such as the Dickkopf 
proteins attenuate and modulate Wnt signal strength in both β-catenin-dependent and 
independent Wnt signaling modes (212-214).  Wnt signaling also exhibits extensive 
cross-talk with other EMT-promoting pathways, most notably the Notch pathway (215-
217). 
 
1.8 Notch and EMT 
Notch signaling (Fig. 4) is relatively simple compared to other EMT-related 
pathways such as TGF-β and Wnt / Frizzled signaling, and has considerable cross-talk 
with both, being required for TGF-β-induced EMT in some cases (218). Notch signaling, 
similar to the TGF-β and Wnt / Frizzled pathways, begins with engagement of a ligand - 
Delta, Lag, or Serrate - by the Notch receptor, triggering cleavage of Notch and release of 
its intracellular domain (219). Cleavage of membrane-bound Notch occurs in two steps, 
the first step is catalyzed by ADAMs family metalloproteases and results in release of the 
extracellular domain of Notch (220-222). Step two is carried out by the activity of the 
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presenilin-nicastrin-Aph1-Pen2 protein complex, which is more commonly referred to as 
-secretase, and releases the intracellular domain of Notch (NICD) which translocates to 
the nucleus (223). Freed NICD displaces co-repressors such as NcoR, SMRT and 
SHARP from their interaction with Notch target-gene bound CSL, clearing the way for 
recruitment of co-activators such as Mastermind (224-230).  During EMT, the most 
important Notch targets appear to be the E-cadherin reprssors snail and slug. Snail and 
slug are up-regulated directly via association of the NICD with their promoters and Snail 
indirectly via induction of lysyl oxidase, which stabilizes Snail via phosphorylation (149, 
231, 232).  
 
1.9 Snail 
 Snail promotes EMT in response to all the major pathways known to elicit EMT, 
such as the Wnt, Notch, TGF-β, and FGF signaling pathways (176, 182, 208, 211, 231, 
233). Snail's function in EMT is centered around its role as a repressor of E-cadherin 
gene expression (234, 235), although it also targets other epithelial genes such as ERα,  
MUC1 and tight junction proteins (236-238). Snail effects repression of these genes by 
recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex and C-
terminal binding protein (CtBP) (239-241). Snail also promotes cell survival via 
induction of cell cycle arrest (242-244), and suppression of the PTEN phosphatase (245). 
Consistent with the aggressive, metaplastic nature of many ERα- tumors, Snail 
expression is restricted by estrogen signaling (246), suggesting the existence of a Snail- 
ERα regulatory loop that governs cellular plasticity. ERα signaling represses Snail 
indirectly by activating transcription of MTA3, a component of the Mi-2 / NuRD 
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transcriptional repressor, which then targets Snail (246). Like many other factors 
involved in EMT, Snail is associated with metastasis, recurrence, and poor prognosis 
(247-249). 
 
 
 
 
 
Figure 4. Notch signaling. Binding of a Delta - Serrate - Lag2 family ligand by the Notch receptor triggers cleavage of the receptor 
and releases of the intracellular domain of Notch (NICD). Cleavage takes place in two steps, the first is an extracellular cleavage 
event mediated by TACE  that primes the receptor for the second cleavage event in the transmembrane domain performed by the γ-
secretase complex. Once released, the NICD translocates to the nucleus where it disrupts interactions between the transcription 
factor CBL and co-repressors such as NcoR and SMRT. Co-activators such as Mastermind and then free to bind to CBL, which 
constitutively resides on the promoter regions of Notch target genes.    
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1.10 Twist 
 Similar to Snail proteins (Fig. 5), Twist has been reported to promote EMT via 
suppression of E-cadherin (161, 182, 250, 251), and up-regulation of genes associated 
with mesenchyme such as N-cadherin, FGFR2, and cadherin 11 (187, 252, 253). While 
the mechanisms by which Twist activates or represses transcription has not been solved 
fully, it is clear that dimerization partner selection is the major determinant of Twist 
activity (252, 254). Twist homodimerization or dimerization with E2A E12 results in 
transactivation (252, 254), while partnering with Id proteins and other bHLH repressors 
results in repression (252). In addition to targets associated with EMT, twist has profound 
effects on cell survival and genome integrity (255, 256). Twist represses expression of 
p14 (ARF) while upregulating AKT2, leading to checkpoint failure, drug resistance, and 
genomic instability (257, 258). Twist is also a key mediator of drug resistance induced by 
NF-kB activation, and appears to regulate phosphorylation of Bcl-2 proteins (259). 
Regulation of twist occurs mainly at the transcriptional level. Twist can be induced by 
Wnt, hypoxia, Notch, TGF-β, NF-kB, and VEGF, amongst other pro-EMT pathways and 
stimuli (162, 182, 259-261). Twist is a direct target of HIF1α and HIF2α and is associated 
with tumor vascularity, suggesting that Twist participates in angiogenesis and may 
promote metastasis via enabling access to the bloodstream as well as through EMT (162, 
165, 262).  In additon to its role in EMT and angiogenesis, Twist is associated with 
distant metastasis, recurrence, poor prognosis, and tumor vascularity (162, 165, 263-267), 
a common finding with transcription factors related to EMT. 
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Figure 5. Regulation of  the E-cadherin repressors snail, slug, and twist in breast cancer.  Snail, slug, and twist are induced by 
activation of  multiple signaling pathways such as the Wnt / β-catenin, TGF-β, and notch pathways (black arrows), as well as by 
microenvironmental stimuli (hypoxia and inflammation, blue and red arrows, respectively). In breast tissue, estrogen signaling 
represses snail via MTA3 and is repressed by snail, consistent with the agressive nature of ERα-negative tumors. The output that 
procedes from these pro-emt factors promotes motility and invasiveness through repression of cadherins and desmosomal 
proteins, as well as survival via repression of p14ARF and PTEN and up-regulation of AKT2.  
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1.11 Slug 
The zinc finger transcriptional repressor slug (SNAI2) provides a link between 
EMT and acquisition of stem-cell like properties by tumor-initiating cells. Slug facilitates 
EMT downstream of multiple pathways such as the TGF-beta, notch, Wnt, and FGF 
pathways (182, 232, 268, 269), which promote maintenance of stem cell identity (270-
276).  Additionally, slug is a key player in stem cell biology, with important 
transcriptional targets unrelated to EMT such as PUMA and BRCA2 (124, 277-283). 
Consistent with the current thought on stem-cell like properties of tumors cells in basal-
like carcinomas, slug is a driving force behind the basal phenotype (114). Slug also 
predicts poor prognosis and recurrence in multiple tumor types including breast cancer, 
which further suggests that slug is at the heart of the aggressive nature of basal-like 
carcinomas (127, 168, 169, 248).  In the context of EMT, slug is best known as a 
repressor of E-cadherin expression (129). However, slug targets multiple epithelial genes 
such as high molecular weight keratins and desmosomal proteins to promoter cellular 
motility and suppression of the epithelial phenotype (158, 268, 284). Multiple studies 
have implicated slug in DNA damage responses, particularly those of stem/progenitor 
cells and transformed cells (124, 278, 279, 282, 283, 285). Slug promotes survival in the 
face of genotoxic stress, centered on its ability to stifle p53-mediated induction of the 
pro-apoptotic protein PUMA (278).  This fact may explain the frequency of recurrence in 
basal-like carcinomas of the breast, which frequently display initial sensitivity to 
treatment but have high recurrence rates (122). Structurally, slug consists of a SNAG 
domain that effects transcriptional repression and five DNA-binding ZNF domains, and is 
the most conserved of all mammalian snail homologs (286). The SNAG domain, which is 
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common to all snail family proteins and multiple other oncogenes, functions as an 
interaction domain with scaffolding proteins to recruit macromolecular repression 
complexes to slug target genes (287). Examples of this include recruitment of Ajuba LIM 
proteins, which in turn recruit protein arginine methyltransferase 5 (PRMT5) to repress 
transcription (287-289), and recruitment of the Sin3A/Histone Deacetylase 1 
(HDAC1)/HDAC2 repressor complex (239), both to the E-cadherin promoter. Several 
studies have shed light on the regulation of slug expression. The promoter region of 
SLUG contains multiple regulatory elements, including MyoD, TCF/LEF, AhR, E2A-
HLF, and SMAD-responsive regions (184, 290-293), all of which facilitate 
transactivation of the SLUG gene. However, the factors that restrict inappropriate slug 
expression have thus far remained unidentified.  
 
1.12 Comparison of pathological and developmental EMT 
 
 EMT in developmental contexts is tightly controlled in space and time (294).  
Often, likely always, multiple pathways associated with EMT induction are 
simultaneously activated, and crosstalk between them confers the precision needed for 
proper development of embryonic and mature tissues. An example of this precision can 
be found during gastrulation, which is tightly controlled by the BMP antagonist Noggin 
(138). Spatially and temporally controlled NOG expression brings gastrulation to an end 
in an appropriate time frame, while still allowing for EMT-like events to shape the 
tailbud. Mice mutant for NOG fail to bring a halt to the ingressive cell movements of 
gastrulation, and NOG null mice have severe skeletal defects and mesenchymal 
hyperplasias by the time of lethality on embryonic day 18.5 (295, 296). Additionally, 
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mice and humans haploinsufficient for NOG suffer from skeletal defects such as carpal 
and tarsal fusions, which highlights the necessity for an "off-switch" for non-pathologic 
EMT processes to function normally (296). In the developing heart, defects in NOG or 
the EMT "on-switch" BMP2 leads to defects in the endocardial cushions and derived 
structures, and proper functioning of both switches requires input from the notch, leptin, 
Wnt, and HGF signaling pathways to ensure appropriate expression of the downstream 
targets slug and snail (136, 148, 149, 296-298). This implies that one of the ways that 
EMT is suppressed in mature tissues is a requirement for convergence of mulitple EMT-
promoting pathways to initiate and sustain EMT, and may explain the rarity of EMT 
events observed in solid tumors, since activation of an EMT promoting pathway could be 
sufficient to drive tumor growth without reaching the signal threshold for EMT. That is, 
pro-EMT signals must hit a specific pitch before the anti-EMT signals are overridden and 
EMT occurs. Thus it appears one of three phenomena drive pathologic EMT: a relentless 
on-switch, a malfunctioning or absent off-switch, or the creation of new on-switches 
which results in enough "on" signal to drive EMT (Fig. 6). 
 
 Overexpression of EMT-promoting factors and loss of antagonistic factors has 
been reported in many cancers (173). An important example of a malfunctioning switch 
was recently elucidated by Gomis et al, when they discovered that loss of the LIP isoform 
of the transcription factor C/EBPβ eliminated the cytostatic effects of TGFβ in human 
breast tumors (202). This malfunctioning switch allows the cancer cells to receive the 
benefit of the pro-invasive properties of TGFβ and explains the biphasic action of TGFβ 
in tumors. As more intrinsic breaks and feedback loops on the EMT process are 
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uncovered, the apparently contradictory tissue specific roles of other EMT-related factors 
such as Notch may be understood more fully (299).  
 
1.13 Pathologic vs. non-pathologic EMT: role of hypoxia 
 Two major EMT-promoting switches are present under pathologic conditions that 
are absent in developmental EMT: hypoxia and inflammation. Hypoxia is present even in 
microscopic tumors, and contributes to tumor progression, angiogenesis, and 
radioresistance (300-302). Hypoxia results in prolylhydroxylase-dependent stabilization, 
dissociation from the VHL ubiquitin ligase, and activation of hypoxia-inducible factor 1-
α (HIF1α), as well as activation of HIF2α, both of which activate genes involved in 
angiogenesis as well as those involved in EMT (162, 303). HIF1α directly binds the 
hypoxia response element (HRE) in the Twist1 proximal promoter region in response to 
hypoxia and induces EMT, an effect reversible by siRNA directed to Twist (162). HIF2α 
has also been reported to transactivate Twist in response to hypoxia, but intriguingly 
HIF2α targets intronic HREs that are not responsive to HIF1α (262). This is particularly 
interesting in light of previous reports that HIF1α and HIF2α are differentially activated 
during acute and prolonged hypoxia in tumors, where high HIF2α expression correlated 
with VEGF expression, advanced clinical stage, and poor prognosis (304). This would 
suggest that during initial acute hypoxia HIF1α expression triggers angiogenesis and pro-
survival Twist expression, while continued low-level hypoxia causes continued 
expression of Twist via HIF2α and promotes EMT and metastasis. As HIF-driven EMT 
appears to be dependent upon Twist, arrival in a mature, oxygenated tissue may decrease 
Twist expression sufficiently to allow for MET and establishment of metastatic colonies. 
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 Several other factors appear to be required for hypoxia driven EMT. The Notch 
signaling pathway is necessary to convert the hypoxic stimulus into a pro-EMT signal 
and promote Snail expression directly and via lysyl oxidase mediated phosphorylation of 
Snail (231). Additionally, increased expression of the urokinase-type plasminogen 
activator receptor (uPAR) and activation of cell signaling factors downstream of uPAR 
Figure 6. Pathological and developmental EMT. Developmental and pathological EMTs and METs share many common features 
such as loss of E-cadherin in EMT, as shown in the orange panel. Developmental EMT (orange and yellow panels) is characterized 
by strict spatial and temporal control, while pathological EMTs such as those occurring during metastasis and fibrosis have lost or 
eluded the molecular brakes on the EMT process. Pathological EMTs also occur in microenviroments rife with EMT-promoting 
hypoxic and inflammatory stimuli, which may disappear during extravasation thereby facilitating MET. The metastatic colony soon 
generates hypoxic and inflammatory stimuli of its own, maintaining the plasticity of the cells to spread further even if the original 
tumor is removed. 
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such as Akt and Rac1 have been shown to be required for full manifestation of the EMT 
phenotype in response to hypoxia (305). Blockage of either Notch or uPAR signaling in 
these studies was sufficient to halt hypoxia-induced EMT, and activation of Notch or 
overexpression of uPAR could substitute for hypoxia in EMT promotion. This is further 
evidence that EMT signaling must reach a threshold before EMT is initiated, and that 
tumor-associated hypoxia represents a pro-EMT signal that tilts the balances in favor of 
EMT but is not sufficient to initiate it alone, else nearly all solid tumors would display 
EMT. Hypoxia also contributes to pathogenic EMT in non-transformed cells, such as 
during kidney fibrosis (306, 307), suggesting that EMT and transformation are separate 
processes that can employ many of the same effectors. 
 
1.14 Pathologic vs. non-pathologic EMT: role of inflammation 
 The most well known link between inflammation and cancer is the transcription 
factor NF-κB, which activates transcription of genes that promote inflammation, cell 
survival, EMT, and cellular transformation, both initiating and feeding forward in these 
repsonses (308). NF-κB mediates EMTs initiated by the pro-inflammatory cytokine 
Tumor Necrosis Factor-α (TNFα) via induction of the E-cadherin repressors ZEB-1 and 
ZEB-2, and  up-regulates Twist and Snail  (259, 309, 310).  In addition to activation by 
inflammatory stimuli, NF-κB-driven EMT can be activated by genotoxicants such as 
7,12-dimethylbenz(a)anthracene (DMBA), and by hypoxia (311, 312). NF-κB can also be 
activated by loss of E-cadherin via p38 MAPK, providing a feed-forward mechanism for 
sustained EMT signaling (313). NF-κB can also feed forward on itself (314), suggesting 
another possible mechanism by which NF-κB signaling can sustain EMT.  Ectopic 
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expression of supraphysiological levels of active NF-κB is also capable of inducing EMT 
(309), indicating that NF-κB activity represents another EMT on-switch that initiates 
EMT upon reaching of a threshold signal. Physiological levels of cancer-related NF-κB 
activity do appear to be sufficient to drive EMT on their own, given the prevalence of 
aberrant NF-κB activation and rarity of EMT in breast cancers (116, 132, 315). EMT in 
breast cancer is often associated with ERα negative tumors, which have poorer 
progonosis than ERα positive tumors (117). Therefore, it is not surprising that ERα 
represses expression of the RelB subunit of NF-κB (316). ERα is in turn suppressed by 
the NF-κB target Snail (238), which is itself a target of suppression by MTA3, a 
downstream effector of ERα (246). 
 
 Inflammtory NF-κB-mediated signialing pathways also have extensive cross-talk 
with other EMT-promoting factors such as Wnt, Notch, HIF1α, and TGF-β (317-323). 
NF-κB transactivates the HIF1α promoter, and is required for hypoxia-induced HIF1α 
accumulation (321). HIF1α returns the favor by promoting NF-κB activation via 
phosphorylation of IKK and NF-κB itself, suggesting cooperation between hypoxia and 
inflammation in pathogenic EMT (324). Inflammatory signaling pathways can also 
crosstalk with HIF1α in an NF-κB-independent fashion, as LPS-induced HIF1α 
activation appears to be NF-κB-independent but is sensitive to antioxidants (325), and 
processes that generate reactive nitrogen species can stabilize HIF1α through S-
nitrosylation of HIF1α's oxygen-dependent degradation domain, preventing interaction 
with VHL (326). Knowledge of the extensive entanglements between the various EMT-
promoting pathways has provided numerous potential therapeutic targets, however, 
  33
relatively little work has been done to elucidate the factors that restrain EMT in normal 
tissues and less advanced cancers. 
 
1.15 SIM2 
 In the developing Drosophila CNS, specification of the CNS midline is dependent 
upon the basic helix-loop-helix Per-Arnt-Sim transcription factor single-minded (sim), 
which serves as the master regulator of midline differentiation (327, 328). Singleminded-
2 (SIM2) is one of two vertebrate orthologs of the Drosophila sim (dsim) protein, but it 
differs in functioning as a transcriptional repressor (329-332). SIM2 was initially 
identified by positional cloning around the DS (DS) critical region of chromosome 21 and 
is believed to contribute to many of the physiological abnormalities associated with 
trisomy 21 (333). SIM2 functions as a heterodimer with ARNT, similar to drosophila 
counterpart dsim that dimerizes with the ARNT ortholog Tango to control expression of 
midline genes in the central nervous system (CNS) (334, 335). SIM2 is expressed in 
multiple tissues including the kidneys, lungs, brain, and breast, in both adult and 
developing tissues (329, 336-338). Sim2 plays an important role in development, as Sim2 
null mice die shortly after birth due to multiple abnormalities, including cleft palate, 
improper diaphragm development, and rib defects (337, 338). The molecular mechanisms 
controlling these processes are complex and involve the concerted actions of many 
factors, and suggesting a master regulatory role for SIM2 in the many developmental 
processes that are severely disrupted in Sim2 null mice. Indeed, SIM2s, a splice variant 
of SIM2, was recently identified as a regulator of MMP3 gene expression, which plays a 
critical role in the development of the palate, mammary gland, and neuromuscular 
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junctions (15, 339-342). As the phenotype of MMP3 null mice is significantly different 
from and less severe than that of Sim2 null mice, it is clear than many more important 
developmental targets of SIM2 remain to be elucidated. 
 
1.16 The Down syndrome (DS) tumor profile 
 Individuals with DS have a markedly different tumor spectrum than the general 
population. Specifically, leukemias are greatly increased while solid tumors are decreased 
in DS patients (343-350). Most striking is the profound protection women with DS enjoy 
from breast cancer, with as much as 25-fold protection compared to the non-DS 
population (344, 347-350). Recently, this solid tumor protection was proposed to be due 
to at least in part to gene dosage-mediated increases in ETS2 levels (351). However, this 
cannot explain the protection that women with DS enjoy, as there is overwhelming 
evidence that ETS2 acts as an oncogene in breast tissue by promoting tamoxifen 
resistance and suppressing the tumor suppressor BRCA1 (352-355). Therefore, other 
mechanisms must be invoked to fully explain the tumor spectrum of DS patients. 
 
 Due to its position in the DSCR of chromosome 21, and its roles in regulating 
responses to xenobiotics and hypoxia, SIM2 is a strong candidate for contributing to 
trisomy 21-related solid tumor suppression. Other laboratories have reported that SIM2s 
is oncogenic in the pancreas, prostate, and colon (356-359), a conclusion based largely on 
the observation that antisense oligos targeted to the 3' untranslated region of the SIM2s 
mRNA resulted in apoptosis. However, as loss of tumor suppressors such as VHL can 
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lead to senescence (360), this conclusion requires mechanistic support, especially in light 
of the frequency of SIM2s loss in breast tumors (336).  
 
1.17 The mechanism of SIM2-mediated tumor suppression 
To attempt to shed light on the true nature of SIM2s as relates to cancer, we used 
a retroviral shRNA system to silence SIM2s in the relatively non-invasive breast cancer 
cell line MCF-7, which expresses high amounts of SIM2s relative to more invasive cell 
lines (336). Based on previous studies from MDA-MB-435 cells, we hypothesized that 
loss of SIM2s would confer enhanced invasiveness and tumorigeneic properties. As 
expected, silencing of SIM2s lead to enhanced invasiveness, and also promoted EMT, 
xenograft tumor growth, and metastasis. Investigation into the mechanism underlying 
these observations revealed that the oncogenic E-cadherin repressor slug and the 
invasion-associated metalloprotease MMP2 are direct targets of SIM2s-mediated 
transcriptional repression. Furthermore, SIM2s binds the slug promoter directly and 
represses transcription, making it the first known repressor of slug expression. Sim2-/- 
mammary glands also displayed hallmarks of EMT such as E-cadherin loss and increased 
nuclear accumulation of β-catenin, suggesting that Sim2s' roles in regulating slug is 
conserved amongst mammals. Silencing of SIM2 also severely disrupted acinar 
morphogenesis in untransformed MCF-10A cells, but was not sufficient to induce EMT. 
 
 As slug plays an important role in stem cell biology and SIM2i cells were much 
more tumorigenic than their control "scrambled" (SCR) counterparts, we asked whether 
SIM2 loss affected self-renewal capacity or expression of stem cell markers. When 
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grown under low attachment conditions in normal growth media, SIM2i cells had a 
decided advantage in self-renewal as measured by mammosphere formation, but this 
effect was masked by supplementation with growth factors. Using commonly used 
markers for tumor-initiating cells in MCF-7 populations, we found that SIM2i cells had a 
significantly larger number of putative tumor-initiating CD29+ CD24lo cells, consistent 
with their enhanced tumorgenecity. In both stem cells and cancer cells, slug has been 
reported to enhance cell survival in the face of DNA damage, and therefore we asked 
whether depletion of SIM2s enhanced chemoresistance. MCF-7 cells infected with the 
SIM2-specific virus (SIM2i) were resistant to doxorubicin, but not ionizing radiation 
when compared to SCR cells. Additionally, we found that the reported slug target PUMA 
was not induced in response to DNA damage in SIM2i cells, consistent with their high 
levels of slug expression. Interestingly, SIM2s deficient MCF-7 cells also failed to induce 
the cyclin-dependent kinase inhibitor p21/ WAF1/CIP1 under conditions where it was 
robustly induced in SCR cells, suggesting a role for SIM2 in DNA damage signaling. 
Further examination of the DNA damage response in SIM2i cells revealed that they were 
p53 positive, and had extremely elevated constitutive p53 levels, with no mutations in 
p53. While apparently insufficient to drive expression of p21 or PUMA, other p53 targets 
such as MDM2 and NOXA were induced similarly in both cell types in response to DNA 
damaging agents. ChIP analysis of the p21 promoter confirmed that SIM2 binds the p21 
promoter near the p53 response element in response to doxorubicin and ionizing radiation 
(R. Metz, unpublished results), raising the question of whether SIM2 and p53 interact 
either directly or in a complex. Indeed, we observed a DNA-damage dependent 
interaction between SIM2 and p53, which occurred with 4 hours of DNA damage. We 
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also found that SIM2 is itself stablized by DNA damage, while its RNA expression 
remains unchanged. Our studies suggest strongly that SIM2s is a tumor suppressor, 
although it is possible that SIM2 has tissue-specific activities that make tumor-promoting 
in other tissues. Based on our data presented here and published work on slug, EMT, and 
basal-like carcinomas of the breast, we hypothesize that SIM2 loss contributes to the 
basal phenotype and may be a useful diagnostic marker for these tumors.   
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CHAPTER II 
MATERIALS AND METHODS 
 
2.1 Cell line maintenance and drug treatment  
 MCF7 cells were maintained in DMEM supplemented with 10% fetal bovine 
serum and 1% penicillin and streptomycin.  MCF10A cells were maintained in 
DMEM/F-12 supplemented with 5% fetal bovine serum, 1% penicillin and streptomycin 
as well as 20 ng/ml epidermal growth factor, 0.5 µg/ml hydrocortisone, 100 ng/ml 
cholera toxin and 10 µg/ml insulin. All cells were grown in 5% CO2 at 37oC. 
 
2.2 Plasmids 
 A 3,280 bp region of the human SLUG gene promoter region was amplified from 
human genomic DNA (Roche) using Accuprime Taq DNA polymerase (Invitrogen) and 
the primers F 5’-GCC TAT GCC ACA CTC TGG TT-3’ and R 5’-GGC GCC TCT GAA 
GTC ACC-3’ and cloned into the pGL3-basic luciferase reporter vector (Promega). The 
human SIM2s expression vector has been described previously (336). The human SIM2-
specific shRNA constructs were generated by ligating a dsDNA insert designed by 
Ambion into their pSilencer U6-retro 5.1 shRNA vector. The dsDNA insert sequences 
were based upon Ambion pre-designed siRNA sequences #3116 (SIM2i #1), 114477 
(SIM2i #2), and 114478 (SIM2i #3). The insert was created by annealing the oligos 5'-
GAT CCG GTC GTT CTT TCT TCG AAT TTC AAG AGA ATT CGA AGA AAG 
AAC GAC CTC TTT TTT GGA AA-3’ (top) and  5'-AGC TTT TCC AAA AAA GAG 
GTC GTT CTT TCT TCG AAT TCT CTT GAA ATT CGA AGA AAG AAC GAC CG-
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3' (bottom) for 3116;  5'-GAT CCG CAG TGA CCT TCT GTA CAC TTC AAG AGA 
GTG TAC AGA AGG TCA CTG CTT TTT TGG AAA-3' (top) and AGC TTT TCC 
AAA AAA  GCA GTG ACC TTC TGT ACA CTC TCT TGA AGT GTA CAG AAG 
GTC ACT GCG-3' (bottom) for 114477; and 5'-GAT CCG CGG GCA ACA GTA TTT 
ATG ATT CAA GAG ATC ATA AAT ACT GTT GCC CGT GTT TTT TGG AAA-3' 
(top) and 5'-AGC TTT TCC AAA AAA CAC GGG CAA CAG TAT TTA TGA TCT 
CTT GAA TCA TAA ATA CTG TTG CCC GCG-3' (bottom) for 114478 to yield 
overhangs compatible with the vector. The scrambled control vector was provided by 
Ambion. 
 
2.3 RNA isolation and real time RT-PCR 
 RNA was isolated using a Qiaquick RNeasy Mini kit with Qiashredder columns 
(Qiagen) and DNase digested (Roche).  Two µg of RNA was reverse transcribed with 
Superscript II Reverse Transcriptase (Invitrogen) with an oligo d(T)12-18 primer.  Relative 
quantitative PCR was performed using Sybr Green master mix and cDNA-specific 
primers.  TBP was used as the housekeeping gene.  Data were collected using ABI 7500 
system software, and analyzed by the CT method.  Primers used for real time RT-PCR 
are shown in the table 3.  
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Table 3. Real-time RT-PCR primers. 
Gene Forward Primer Reverse Primer 
ATM CCG ACG GGC CGA ATG T AGC CGC AGA GCA CGG TAT 
ATR TTG CCA ACG TTT TCG ACT TTC TCC TAA AGT TCG AAT GAG AGC AGA A 
β2M CGC  TCC GTG GCC TTA GC AAT CTT TGG AGT ACG CTG GAT AGC 
BCL2 CAT GTG TGT GGA GAG CGT CAA GCC GGT TCA GGT ACT CAG TCA 
BID CTT TTT CTC TTT CCA TGA CAT CAA GA GGG CAT CGC AGT AGC TTC TG 
BIM CGG TCT CCT GGT GCC ATT AT AGC TCG GTG TCT TCT GAA ACG 
BRCA1 AGC GGT AGC CCC TTG GTT GCG CAG TCG CAG TTT TAA TTT 
 
BRCA2 CGC GGT TTT TGT CAG CTT ACT 
 
ACG ATA TTC CTC CAA TGC TTG GT 
 
E-cadherin CAC AGA CGC GGA CGA TGA T GAT CTT GGC TGA GGA TGG TGT AA 
ERα TCT GCC AAG GAG ACT CGC TAC T CGT TAT GTC CTT GAA TAC TTC TCT 
TGA 
GATA3 CTG GCT CGC AGA ATT GCA AAC TGG GTA TGG CAG AAT AAA ACG 
Keratin 18 GAG GCT GAG ATC GCC ACC TA CCA AGG CAT CAC CAA GAT TAA AG 
MDM2 GGG ACG CCA TCG AAT CC TGA ATC CTG ATC CAA CCA ATC A 
MDM4 CAG CAG GAG CAG CAT ATG GTA T AGA AGC TCT GAC GTC CCA GTA GTT 
MMP2 CAA GGA GTA CAA CAG CTG CAC TGA TA GGT GCA GCT CTC TCA TAT TTG TTG C 
MMP3 TTC CTG ATG TTG GTC ACT TCA GA TCC TGT ATG TAA GGT GGG TTT TCC 
MMP14 GCC TGC GTC CAT CAA CAC T ACA CCC AAT GCT TGT CTC CTT T 
N-cadherin CAG CAA CGA CGG GTT AGT CA  TGC AGC AAC AGT AAG GAC AAA CA 
NOXA CTG CAG GAC TGT TCG TGT TCA GGA ACC TCA GCC TCC AAC TG 
p21 CCT AAT CCG CCC ACA GGA A AAG ATG TAG AGC GGG CCT TTG 
p27 GCT AAC TCT GAG GAC ACG CAT TT CGC ATT GCT CCG CTA ACC 
p53 TCT TTG AAC CCT TGC TTG CA CCG GGA CAA AGC AAA TGG 
PR CCG GGC ACT GAG TGT TGA AT GTT TCA CCA TCC CTG CCA AT 
PS2 GTG CCT CGG CTC ACA ACA C CGA TCT CTT TTA ATT TTT AGG CCA AT 
PUMA GGG CCC AGA CTG TGA ATC CT 
 
CGT CGC TCT CTC TAA ACC TAT GC 
SIM2 AGA CAA AGC TGA GAA CAA ACC CCG CAT TCC AGT TTG TCC AT 
SLUG GGC TGG CCA AAC ATA AGC A  CCT TGT CAC AGT ATT TAC AGC TGA 
AA  
SNAIL GCG TGT GGC TTC GGA TGT CTG CAA ATA CTG CAA CAA GGA ATA C  
TIMP2 CCC CTC CTC GGC AGT GT CCC CCT CGG CCT TTC C 
TBP TGC ACA GGA GCC AAG AGT GAA CAC ATC ACA GCT CCC CAC CA 
Vimentin TTC TCT GCC TCT TCC AAA CTT TTC   GGG TAT CAA CCA GAG GGA GTG A  
 
All primers were designed based on the human NCBI reference mRNA sequence using primer 
express software from ABI and purchased from IDT.  
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2.4 Chromatin immunoprecipitation 
 ChIP assays were carried out as described by the manufacturer (Upstate Cell 
Signaling) with a few modifications.  Briefly, cells were fixed with 1% formaldehyde for 
10 minutes.  Crosslinking was stopped by addition of 125 mM glycine.  Cells were 
washed in the presence of protease inhibitors (Complete tablets, Roche), pelleted at 2000 
rpm for 4 minutes at 4oC and resuspended in SDS lysis buffer with protease inhibitors 
(Complete tablets, Roche).  Aliquots of 200 µl (1x106 cells) were sonicated for 10 pulses 
of 10 seconds each to shear chromatin to between 200 and 1500 bp.  The supernatant was 
collected and diluted in ChIP dilution buffer to an appropriate amount.  After pre-clearing 
twice with salmon sperm DNA/protein A agarose-50% slurry in TE/Na azide/0.1% BSA, 
the supernatant was incubated overnight with antibody at 4oC.  Antibodies used were 
normal rabbit IgG (5 µg, Upstate), anti-Sim2 (Rb pAb, 5 µg, Chemicon), and anti-slug 
(Rb pAb, 5 µg, Santa Cruz).  The salmon sperm DNA/protein A agarose-50% slurry was 
then used to collect the antibody complexes for 1 hour at 4oC.  Agarose was pelleted at 
1000 x g at 4oC for 1 minute and washed sequentially with low salt wash buffer, high salt 
wash buffer, lithium chloride wash buffer and TE buffer.  The protein complex was 
eluted with 1% SDS, 0.1 M NaHCO3, and the crosslinking was reversed in 200 mM NaCl 
at 65oC for 4 hours.  Ethanol was added to precipitate the DNA, which was then 
resuspended in TE and digested with proteinase K for 1-2 hours at 45oC.  DNA was 
purified using the Qiaquick PCR purification kit.  PCR was performed with primers 
flanking the CME in the SLUG promoter region (5′- TGT GTC CAC GTG GCT CTA 
AG -3′ and 5′- CGC GTG CTA GCG AGT AAC A -3′), and sites 500-1000 bp upstream 
(5′-ATG CCC GCT CTG ACA ATT T-3′ and 5′-GGT GTG TAA AAA GCA GTG 
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CAA-3′), and downstream (5′-CCA GGT TTC CAG TTT GTG TG-3′ and 5′-TGT GTA 
TGG TCT TCA ATC TA-3′) of the CME primer set. Primers flanking the first two E-box 
elements in the E-cadherin promoter were: 5′- AAA AGC CCT TTC TGA TCC CA -3′ 
and 5′- TGG AGT CTG AAC TGA CTT CCG -3′.     
 
2.5 Western blot 
 Protein was isolated using RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 
1% NP-40, 1% sodium deoxycholate, 0.1% SDS) with protease inhibitors and MG-132 
added or with Nonidet-P40 (NP-40) buffer (20 mM Tris HCl pH 8, 137 mM NaCl, 10% 
glycerol, 1% nonidet P-40, 2 mM EDTA) with protease and phosphatase inhibitors.  
Protein was loaded and run on an 8% or 10% acrylamide gel at 110 V until the dye front 
reached the bottom of the gel.  Protein was transferred to a PVDF membrane (Bio-Rad) at 
100 mA for 2 hours or at 60 mA overnight in a cold room.  Membranes were blocked in 
5% milk and probed with the primary antibody for 2 hours at RT or overnight at 4oC.  
Membranes were washed in PBS, 0.1% Tween-20 and probed with the appropriate 
secondary antibody, anti-rabbit (Bio-Rad) or anti-mouse (Santa Cruz), at 1:5000 for 45 
minutes at room temperature.  Blots were again washed in PBS, 0.1% Tween-20 and 
developed with the ECL Plus Western Blotting Detection System (Amersham). All 
washing, blocking, and antibody incubation steps were peformed with gentle rocking.  
Antibodies used for western blotting and immunostaining are summarized in table 4. 
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Table 4. Antibodies and conditions. 
Antibody Manufacturer Host IF/IHC Conditions WB 
Conditions 
β-actin SIGMA M N/A 1:8000 
Active β-
Catenin Clone 
8E7 
Upstate M M.O.M. kit 
recommedations 
N/A 
Aquaporin 5 Alpha 
Diagnostics 
Rb 1:150 N/A 
BrdU Molecular 
Probes 
 1:50 N/A 
CD31 Santa Cruz G 1:100 N/A 
E-Cadherin BD 
Transduction 
M 1:1000 1:2500 
ERα Santa Cruz  Rb 1:500 1:1000 
γ-H2AX Calbiochem Rb 1:1000 N/A 
Keratin 14 Covance Rb 1:1000 1:2000 
Keratin 18 Neomarkers M 1:500 1:1500 
Ki-67 Santa Cruz  G 1:100 N/A 
Laminin V Chemicon M 1:1000 N/A 
MDM2 Chemicon M N/A 1:1000 
MMP2 Affinity 
Bioreagents 
Rb 1:250 1:2000 
MMP3 Affinity 
Bioreagents 
Rb 1:250 1:2000 
N-Cadherin BD 
Transduction 
M 1:1000 1:2500 
NOXA Abcam M N/A 1:1000 
p21 DAKO M 1:1000 1:2000 
p53 R&D Systems G 1:1000 1:2500 
p53 NeoMarkers M 1:250 1:1000 
PUMA Santa Cruz  G 1:250 1:1000 
Phospho- β-
Catenin 
Cell Signaling Rb 1:250 N/A 
α-Smooth 
Muscle Actin 
SIGMA M 1:1000 1:2000 
SIM2 Chemicon Rb 1:250 1:700 
Sim2s Santa Cruz  G 1:100 N/A 
Slug Santa Cruz Rb 1:500 1:1000 
VEGF DAKO M Manufacturer's 
recommendations 
 
Vimentin Clone 
V9 
Sigma M 1:500 1:1000 
 
N/A indicates that the antibody is suitable for the application but was not used or opimized. 
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2.6 Zymography 
 To determine MMP2 activity, conditioned medium from  cells was concentrated 
~20-fold using Centricon 10 spin concentrators (Amicon).  Equal amounts of protein 
were mixed with Laemmli sample buffer without reducing agents, incubated for 15 
minutes at 37°C, and separated on 8% polyacrylamide slab gels containing 1 mg/ml 
gelatin. Following electrophoresis, gels were placed in 2.5% Triton X-100 for 30 minutes 
then incubated at 37°C in 50 mM Tris-HCl, pH 7.4, containing 5 mM CaCl2 for 18 hrs.  
MMP2 activity was visualized by Coomassie blue staining.   
 
2.7 Stable transduction  
 HEK-293T amphotrophic Phoenix cells were transfected with 15 μg pSilencer 
U6-retro 5.1 retroviral vector (Ambion, Austin, TX) with SIM2-specific insert or a non-
specific "scrambled" insert, or a non-retroviral plasmid (pcDNA3) for mock infection. 
After 24 hours, cells were placed at 32oC.  Viral media was harvested 48 and 72 hours 
after transfection and used to infect cells after passage through a 0.45 μM filter.  Infected 
cells were centrifuged at room temperature immediately after application of viral media, 
and housed at 32oC during infection. 24 hours after the second application of viral media, 
cells were rested for 24 hours in their respective normal growth media before initiation of 
puromycin selection. Selection was considered complete when all mock-infected cells 
had died. 
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2.8 Transient transfection 
 MCF-7 cells were used for all transient transfections.  One hundred ng (0.1 μg) of 
plasmid containing transcription factor was mixed with 0.2 μg of plasmid containing 
promoter construct.  Three μL of Genejuice (Novagen) was used per microgram of DNA.  
DNA and Genejuice were mixed in Opti-MEM media (Invitrogen).  Protein was 
harvested 2 days after transfection, using Reporter Lysis Buffer (Promega).  Luciferase 
activity and total protein were measured as described previously (336).  Luciferase 
activities were normalized to total protein values and are represented as the means ± SE 
for three wells per condition.  
 
2.9 Cell proliferation/death assay 
 Cells were seeded at 25,000 cells/well (MCF-7) or 10,000 cells/well (MCF-10A) 
in triplicate in 6-well plates containing selection medium. Cells were harvested and 
counted with a Coulter counter days 2-7 after plating. For drug-induced cell death assays, 
SCR and SIM2-depleted MCF-7 cells were seeded at 500,000 cells per well in 6-well 
plates.  The next day cells were treated with 1 μM doxorubicin or 10Gy of ionizing 
radiation.  Cells were counted, using a Coulter counter, in triplicate (3 wells) at the time 
of treatment and 24 hours intervals thereafter for 3 days. 
 
 
 
 
 
  46
2.10 Migration and invasion assays 
Migration and invasion were measured using control and matrigel-coated invasion 
chambers (Falcon BD, Franklin Lakes, New Jersey). 12,500 cells were seeded in serum-
free DMEM in the upper chamber with serum-containing medium in the lower chamber 
as a chemoattractant. After 20 hours at 37°C, cells were scraped from the upper chamber 
with a cotton swab, and the underside of the membranes were fixed in 100% MeOH, 
stained with DAPI, and counted. Percent invasion was calculated as per the 
manufacturer’s instructions.  
 
2.11 Immunofluorescence 
 Cells were seeded on cover slips in 6-well plates.  The following day the cells 
were fixed in 3.8% paraformaldehyde and permeabilized with 0.1% Triton X-100 for 15 
minutes at 4oC.  The cells were blocked in 5% BSA for 45 minutes and then probed with 
primary antibody for 2 hours at room temperature.  After washing in PBS, the secondary 
antibody was applied in blocking buffer for 45 minutes at room temperature. The 
secondary antibody was then washed off in PBS and 5ug/mL DAPI was applied for 5 
minutes in the dark at room temperature. After thorough washing in PBS, Cells were 
mounted in Prolong Gold fluorescence mounting media without DAPI (Molecular 
Probes) and allowed to cure overnight before viewing.  DAPI and fluorescent Alexa 
Fluor-conjugated secondary antibodies and phalloidin were purchased from Molecular 
Probes and applied according to the manufacturer’s instructions.  
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2.12 Immunohistochemistry 
Mammary gland and xenograft tumor sections on Superfrost plus microscope 
slides were baked at 62oC for 30 minutes in an upright position then rehydrated by 
sequential washes in xylene and a series of graded ethanol washes. Antigen retrieval was 
performed for 10 minutes at 98°C in 0.01 mol/L sodium citrate buffer, pH 6.0, in a 
microwave oven.  When appropriate, sections were incubated in 3% hydrogen peroxide 
for 6 minutes to block endogenous peroxidase activity.  After a 45 minute block in 10% 
serum, the sections were incubated with the primary antibody overnight at 4oC or for two 
hours at room temperature. Secondary detection was performed with a fluorescent 
secondary antibody or the appropriate biotinylated secondary antibody, Vectastain ABC 
elite kit, and DAB (Vector Labs, Burlingame, CA).  
 
2.13 Co-immunoprecipitation 
 Protein samples from MCF-7 cells were harvested in non-denaturing protein lysis 
buffer supplemented with protease and phosphostase inhibtors.  100 were pre-cleared 
twice with salmon sperm DNA/protein A agarose-50% slurry in TE/Na azide/0.1%BSA, 
the supernatant was incubated overnight with antibody at 4oC.  Antibodies used were 
anti-Sim2 (1:100, Chemicon), normal rabbit IgG (1:1000, Upstate), and anti-NFκB p65 
(1:100, Abcam).  The salmon sperm DNA/protein A agarose-50% slurry was then used to 
collect the antibody complexes for 1 hour at 4oC.  Agarose was pelleted at 1000 x g at 
4oC for 1 minute and washed consecutively with low salt immune complex wash buffer, 
high salt immune complex wash buffer, lithium chloride immune complex wash buffer 
and TE buffer.  The pellet was resuspended in 50 μl of 1X SDS-PAGE loading buffer, 
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boiled for 5 minutes and 10 μl of sample was run by SDS-PAGE.  Western blotting was 
performed as described above, with anti-Sim2 and rabbit anti-NFκB p65 (1:1000, 
Abcam) primary antibodies.   
 
2.14 Flow cytometry 
 MCF-7 cells bearing either a control (SCR) or SIM2-specific (SIM2i) shRNA 
expression construct were analysed by flow cytometry according to the protocol 
recommended by BD. Briefly, cells were washed, trypsinized, counted on a Coulter 
counter, and resuspended in PBS, 1% FBS at 2.5 million cells per ml.  250,000 cell 
aliquots of this suspension were incubated with 20 μl of experimental antibodies or 
isotype controls for 30 minutes at RT in the dark as recommended by BD. Cells were 
again washed, resuspended in PBS 1% FBS and analyzed on a FACSCalibur (Becton 
Dickinson Immunocytometry Systems) flow cytometer, equipped with a 15 mW air-
cooled argon laser, using CellQuest (Becton Dickinson) acquisition software.  List mode 
data were acquired on a minimum of 10,000 events falling within light scatter gates set to 
include cells while excluding dead cells and clumps of cells.  Data analysis was 
performed in FlowJo (Treestar, Inc.) using forward and side light scatter to gate the cells. 
Antibodies and isotype controls used in flow cytometry experiments were purchased 
from Becton Dickinson and used according to the manufacturer's protocol. 
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CHAPTER III 
 
LOSS OF SIM2s INDUCES EMT IN MCF-7 CELLS* 
 
3.1 shRNA directed to SIM2s promotes EMT 
 Previously, we have shown that SIM2s expression is lost in human breast tumors 
and correlates inversely with breast cancer cell invasiveness (336). Furthermore, 
reintroduction of SIM2s into highly invasive cancer cells resulted in decreased 
proliferation, migration and invasion. To determine if loss of SIM2s is sufficient to cause 
progression, MCF-7 cells were transduced with either a non-specific “scrambled” control 
(SCR) shRNA retroviral construct, or one of three SIM2-specific shRNA constructs 
targeting different regions of the SIM2 mRNA (SIM2i114478, and SIM2i3116 and 
SIM2i114477, Fig. 7A). Significant reduction in SIM2s protein was observed in the 
SIM2i114478, and SIM2i3116 cell lines (Fig. 7B), but not in SIM2i114477 (data not shown).  
In three independent infections, MCF-7 SIM2i3116 and SIM2i114478 cells showed 
significantly enhanced invasive ability (Fig. 6C) and underwent a morphological change 
from the cobblestone epithelial shape typical of MCF-7 cells to a spindly mesenchymal 
cell-like morphology (Fig. 7D), suggesting that loss of SIM2s expression had induced 
EMT.  
 
*Part of the data reported in this chapter is reprinted with permission from “Loss of singleminded-2s in the 
mouse mammary gland induces an epithelial-mesenchymal transition associated with up-regulation of slug 
and matrix metalloprotease 2” by Laffin et al., 2008. Molecular and Cellular Biology, 2008 
Mar;28(6):1936-46. Copyright 2008 American Society for Microbiology 
  50
To confirm that the morphological changes observed with the loss of SIM2s was 
indeed an EMT, we utilized the SIM2i3116 MCF-7 cell line, which will be referred to from 
here on as SIM2i, to assay the expression of additional epithelial and mesenchymal cell 
markers.  Western blots (Fig. 7E), differential interference contrast microscopy (Fig. 8A) 
and immunofluorescence analysis (Fig. 8B) confirmed that SIM2i cells lost expression of 
keratin 18 and E-cadherin and increased expression of N-cadherin and vimentin. 
Although SIM2i MCF-7 cells express mesenchymal markers and do not express E-
cadherin, increased nuclear accumulation of ß-catenin was not detectable by antibodies 
against the active, non-phosphorylated (S37, T41) form (data not shown). There was, 
however, a marked increase in nuclear accumulation of the phospho-S33, S37, T41 form 
of ß-catenin (Fig. 8B), a phenomenon recently shown to be associated with poor 
prognosis in aggressive breast carcinomas (361). Changes in SIM2i protein levels were 
accompanied by dramatic decreases in keratin 18 and E-cadherin message and increased 
N-cadherin and vimentin mRNA, as measured by real-time RT-PCR (Fig. 8C).  Together, 
these data indicate that loss of SIM2s in MCF-7 cells results in a morphological, 
functional and biochemical switch from an epithelial to a more mesenchymal-like 
phenotype.  
 
 
 
 
 
 
  51
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2 SIM2i MCF-7 cells form rapidly growing ERα- tumors in nude mice 
To assess the tumorigenic effects of SIM2s loss, we compared tumor forming 
ability of SIM2i cells to control cells using a nude mouse xenograft assay. SIM2i cells 
rapidly developed into tumors that were three times larger than controls by day 10 (Fig. 
9A). SIM2i cell derived tumors maintained this size advantage throughout the experiment 
and were 6-fold larger than SCR-derived tumors with an average weight 7-fold higher 
than control tumors at the conclusion of the study seventeen days after injection (Fig. 
9B). SIM2i tumors appeared to be more vascularized than control tumors (Fig. 9C), an 
observation that was confirmed by increased CD31 and VEGF immunoreactivity of 
SIM2i-derived tumor sections (Fig. 9D). Quantification of BrdU-positive cells from  
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Figure 7. Silencing of SIM2s causes EMT in MCF-7 cells. (A) Structure of the SIM2s mRNA transcript showing 
region targeted by shRNA constructs. Exons are indicated by numbered boxes. (B) Infection of MCF-7 cells with 
shRNA constructs SIM2i3116 (SIM2i) or SIM2i114478 (SIM2i2) resulted in decreased SIM2s protein levels in 
comparison to a non-specific control shRNA construct (SCR). SIM2i3 was ineffective (data not shown). (C) Down 
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* indicates p<0.05. (D) Phaloidin staining demonstrates that decreased SIM2s expression correlated with loss of 
epithelial morphology and acquisition of a more spindly appearance. Bar = 100μm. (E) Western analyses of SCR 
Keratin, E-cadherin, N-cadherin, and Vimentin indicated that MCF-7 cells targeted for SIM2s down regulation 
lose epithelial markers and gain mesenchymal ones. 
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xenograft tumor sections showed a 35-fold increase in SIM2i cell proliferation (Fig. 9D; 
SCR = 1.1% ± 0.543%, SIM2i = 35.1% ± 2.24%), suggesting a link between increased 
vascularity, cell proliferation and tumor growth in SIM2i-derived tumors.  Similar to our 
in vitro studies (Fig. 8), SIM2i-derived tumors displayed signs of EMT with decreased E-
cadherin and increased vimentin staining (Fig. 9D). 
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SIM2i cells. (C) Real time RT-PCR analyses of SCR and SIM2i MCF-7 cells for expression of Keratin 18, E-
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Normally, tumor development in the MCF-7 xenograft model requires exogenous 
estrogen to sustain growth. Therefore, we were surprised to see tumors develop so rapidly 
in the absence of estrogen. The accelerated rate of SIM2i tumor growth coupled with the 
apparent estrogen-independent nature of this growth prompted us to look at ERα 
expression. Indeed, ERα was undetectable in SIM2i-derived tumors by 
immunohistochemistry (Fig. 9D), or in SIM2i MCF-7 cells by either real-time RT-PCR 
(Fig. 10A) or western blot (Fig. 10B).  Furthermore, SIM2i cells no longer responded to 
estrogen treatment as measured by induction of the estrogen-responsive genes PR and 
PS2 (Fig. 10C and 9D). The striking increase in SIM2i MCF-7 cell tumorigenesis 
confirms that loss of SIM2 has functional consequences in vivo and provides further 
evidence that SIM2s may represent an important hurdle to breast cancer progression.  
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3.3 MMP3 and Rac1b are not induced in MCF-7 cells upon loss of SIM2s and MMP 
inhibition does not affect the EMT phenotype 
In previous studies utilizing MDA-MB-435 cells, we reported that MMP3 is a 
direct target of SIM2s-mediated transcriptional repression (362). MMP3 has also been  
MMP3 mRNA
0
1
2
3
4
5
6
Scr SIM2i
MMP3pro
0
500
1000
1500
2000
2500
3000
3500
Basal SIM2s
MMP3pro - Basal
0
10000
20000
30000
40000
50000
60000
70000
Scr SIM2i Scr SIM2i
MMP3B
A
D
C
*
*
R
el
at
iv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
R
el
at
iv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
R
el
at
iv
e 
Ex
pr
es
si
on
Scr SIM2i
Active MMP3
Casein Zymography
Figure 11. MMP3 expression and activity in SCR and SIM2i MCF-7 cells. (A) Basal MMP3 promoter 
activty is increased in SIM2i MCF-7 cells. (B) SIM2s represses expression from an MMP3 promoter 
construct in a dose-dependent fashion. (C) MMP3 mRNA expression is elevated in SIM2i MCF-7 cells. 
(D) Loss of SIM2 has no measurable effect on MMP3 protein secretion (top panel) or activation (bottom 
panel) in conditioned media from MCF-7 cells. 
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reported to be sufficient to initiate EMT via generation of reactive oxygen species and a 
splice variant of Rac1, Rac1b (363). Therefore, we hypothesized that up-regulation of 
MMP3 may contribute to the aggressive, invasive phenotype observed in SIM2s-depleted 
cells. We observed an increase in MMP3 promoter activity in the SIM2i cells, and SIM2s 
retained its ability to repress the MMP3 promoter in a dose-dependent fashion in MCF-7 
cells (Fig. 11A and 10B), consistent with previous results. However, in contrast to our 
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Figure 12. SIM2s inhibits MMP2 expression and activation. (A) Expression of MMP2,MMP14 and TIMP2 was 
increased in SIM2i MCF-7 cells in comparison to control cells. (B) Increased MMP2 mRNA corresponded to 
increased MMP2 protein (top) and activity (bottom) in SIM2i MCF-7 (C) Immunostaining of SCR and SIM2i-
derived tumor sections indicated that MMP2 expression was significantly elevated in SIM2i-derived tumors. (D) 
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indicates p<0.005, Bar = 100μm. 
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findings in MDA-MB-435 cells, MMP3 mRNA expression was not significantly altered 
(Fig. 11C), and MMP3 protein expression and activity were unchanged (Fig. 11D), 
suggesting that this apparently inconsistent result is due to intrinsic differences in basal 
MMP3 expression between MDA-MB-435 and MCF-7 cells. 
 
3.4 SIM2s represses MMP2 expression and activity  
 
As previous work had suggested that SIM2s may regulate several MMPs, we 
measured expression of several MMPs and related factors in SCR and SIM2i cells by real 
time RT-PCR to determine if another MMP could be playing a similar role to MMP3 in 
EMT promotion.  We found MMP2 to be up regulated >4,500-fold in SIM2i cells, while 
others including MMP9 were unchanged (Fig. 12A and not shown).   MMP14 and 
TIMP2, which are required for MMP2 activation, were also up regulated approximately 
6- and 7-fold, respectively, in SIM2i cells (Fig. 12A). The MMP2 mRNA increase 
observed in SIM2i cells was corroborated at the protein and activity levels (Fig. 12B). In 
addition, MMP2 levels were markedly elevated in xenograft tumor sections derived from 
SIM2i cells in comparison to those derived from control cells (Fig. 12C), confirming that 
loss of SIM2s lead to increased MMP2 expression. 
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 Increased MMP2 expression was attributable to de-repression of the MMP2 
promoter, as expression of an MMP2-controlled luciferase reporter was significantly 
higher in SIM2i cells (Fig. 12D). Co-transfection of the MMP2 reporter and increasing 
amounts of SIM2s expression vector into MCF-7 cells resulted in dose-dependent 
inhibition of luciferase activity (Fig. 12E).  These results suggested that MMP2 could be 
playing a role in EMT regulation similar to MMP3, however, we could not modulate 
expression of any EMT-related factors in MCF-7 with MMP inhibitors or free radical 
scavengers, and Rac1b expression was lower after the onset of EMT (data not shown). 
This implies that MMP2 does not regulate EMT in MCF-7 cells, and that protease-
mediated mechanisms are not involved in the EMT observed after SIM2 depletion. 
Recently, other studies have also shown that MMP activity is not required for EMT 
(136). These findings suggest that regulation of MMPs by SIM2s is important for its 
tumor suppressor function but is not the mechanism by which SIM2s regulates EMT-like 
processes. 
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3.5 SIM2s participates in maintenance of E-cadherin expression via repression of 
slug   
 We next explored the possibility that SIM2s may regulate other factors involved 
in EMT. Members of the SNAIL family of transcription factors have been implicated in 
regulation of both normal and pathological EMT events (242, 364-366).  During cancer 
progression, increased SNAIL binding to E-box regulatory DNA elements causes 
transcriptional repression of E-cad, which contributes to transformation, angiogenesis and 
EMT (242, 364-366). To determine if members of the SNAIL family are involved in the 
EMT induced by SIM2s loss, SCR and SIM2i cells were analyzed for snail and slug 
mRNA levels by real time RT-PCR.  SNAIL mRNA levels were not significantly 
affected by SIM2 loss in MCF-7 cells (Fig. 13A). In contrast, slug expression was up 
regulated more than 250-fold in SIM2i cells (Fig. 13A), which corresponded to an 
increase in slug protein levels as determined by Western analysis (Fig. 13B). 
 
Since SIM2s functions as a transcriptional repressor (18, 20, 25), we hypothesized 
that SIM2s directly inhibits slug expression at the promoter level. A luciferase reporter 
under control of the human SLUG promoter was transfected into SCR and SIM2i MCF7 
cells and analyzed for activity.  In SIM2i MCF-7 cells, basal reporter expression was 
increased 10-fold over control cells (Fig. 13C). In addition, we observed concentration-
dependent repression of SLUG promoter-controlled gene expression with increasing 
amounts of SIM2s in MCF-7 cells (Fig. 13D). The human SLUG promoter contains 
multiple putative regulatory elements including E-boxes, xenobiotic response elements 
(XREs), and central midline element (CME) core sequences (Fig. 13E). Using an 
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antibody to SIM2 in ChIP analyses, we found that SIM2s binds a region of the SLUG 
promoter containing the CME and two XRE core sequences in SCR, but not SIM2i MCF-
7 cells (Fig. 13E). Analysis with primer sets 500 bp upstream and 500 bp downstream of 
the CME demonstrate that the binding is specific to the CME region (Fig 12E). SIM2s 
was unable to bind a region of the E-cadherin promoter containing E-boxes that are 
targeted by SNAIL protein family members; however, increased binding of SLUG to this 
region was apparent in SIM2i MCF-7 cells (Fig. 13F).  As the ChIP primers used in our 
study flank the putative CME and two XREs, it seems likely that SIM2s-mediated 
repression of SLUG involves binding of SIM2s to one or more of these elements.  Taken 
together, these data suggest that loss of SIM2s leads to de-repression of SLUG expression 
and increased slug binding to the E-cadherin promoter where it potentially plays a role in 
repressing E-cadherin transcription. 
 
3.6 Sim2-/- mammary glands display hallmarks of EMT 
Our initial analyses of Sim2-/- mammary outgrowths, coupled with in vitro MCF-7 
cell studies, strongly suggest that Sim2s restricts tumor progression associated with 
EMT-like events. To confirm this in vivo, Sim2-/- mammary sections were analyzed for 
various epithelial and mesenchymal markers. Uniform polarity (measured by Aquaporin-
5 staining) and robust E-cadherin staining was observed throughout wild-type mammary 
epithelium, but was totally absent in Sim2-/- glands (Fig. 14A). Not surprisingly, the 
increased invasive ability of Sim2-/- epithelial cells was associated with increased Mmp2 
protein levels (Fig. 14A). These observations strongly suggest that an EMT similar to that 
observed in SIM2i MCF-7 cells had occurred in Sim2-/- glands. This was further 
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supported by increased nuclear accumulation of ß-catenin in Sim2-/- ductal epithelium 
(Fig. 14A). Consistent with our model that SIM2s-mediated repression of SLUG 
suppresses EMT, we found increased slug staining in Sim2-/- glands (Fig. 14A). Taken 
together, these data show that loss of Sim2s during mouse mammary gland ductal 
development results in slug up regulation, loss of epithelial cell characteristics, increased 
Mmp2 expression and invasion into the surrounding stroma, reminiscent of an EMT.  
 
 
 
 
 
 
 
 
 
 
 
 
3.7 Silencing of SIM2 in normal breast-derived cells results in increased motility, 
invasiveness, and abnormal 3D acinar morphogenesis 
 EMT is rarely observed in breast tumors, typically in the most advanced 
metastatic cancers. Therefore, we asked whether silencing SIM2 in non-tumorigenic 
MCF-10A cells was sufficient to cause cellular transformation and / or EMT. SIM2 
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Figure 14. Loss of Sim2s in the mouse mammary gland results in a   phenotype consistent with EMT. Analysis of mouse mammary 
outgrowths from WT and Sim2 -/- mice revealed that loss of Sim2s expression is associated with   events including disrupted polarity as 
measured by aquaporin -5 expression, loss of E-cadherin, up regulation of Mmp2 and increased nuclear accumulation of    ß   -  catenin. 
Consisten with our hypothesis that Sim2s - mediated down regulation of Slug represses EMT, we found that  slug protein levels were 
significantly elevated in Sim2  - / - mammary glands. 
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depletion had no effect on in vitro proliferation rate, consistent with results from MCF-7 
cells (Fig. 15A and not shown). However, SIM2 loss did increase invasiveness and cause 
up-regulation of mesenchymal markers in cells grown as monolayers (Fig. 15A and 15B). 
Gene expression changes were modest, and not statistically significant (Fig. 15C). Thus, 
as expected, silencing of SIM2 was not sufficient to cause EMT in MCF-10A cells. This 
likely reflects that in the tumor-derived MCF-7 cells, other barriers to EMT have been 
lost, or that MCF-7 cells could overcome the cell cycle arrest often seen during EMT (30, 
243, 367, 368). MCF-10A cells can be grown in a matrigel basement as three-
dimensional spheroids, which more closely recreate the natural microenvironment of 
epithelial cells than does monolayer culture (369, 370).  As in the mouse or human 
mammary gland, cells in these spheroids growth arrest and form a hollow lumen through 
an apoptotic mechanism, and in some cases can be induced to differentiate and produce 
milk (30, 371-374). Due to the highly disrupted structure we had observed in Sim2-/- 
mammary glands, we expected that depletion of SIM2 would disrupt acinar structure. By 
day 15, the control SCR MCF-10A cells had formed regular spheres with a single layer of 
polarized cells and a hollow lumen (Fig. 15D). In contrast, SIM2i MCF-10A cells were 
irregular and in some cases multi-lobular, and had small, misshapen, or absent lumens 
(Fig. 15D).  Individual cells could be observed delaminating from the acinar structures  
and invading into the matrigel basement (Fig. 15D), suggestive of an EMT like event. 
However, E-cadherin expression was maintained in the SIM2i acini and no mesenchymal 
markers assayed were seen to be upregulated (Fig. 15D). As in Sim2 -/- mammary 
glands, the cells surrounding the lumens of SIM2i acini were poorly polarized and 
disorganized (Fig. 15D). Although highly abnormal, the SIM2i acini did undergo growth 
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arrest and remained growth factor dependent (not shown), suggesting that loss of SIM2 
expression caused at most a partial transformation.  
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CHAPTER IV 
EFFECT OF DEPLETION OF SIM2s ON SELF RENEWAL AND DNA DAMAGE 
RESPONSES IN MCF-7 CELLS 
 
4.1 Loss of SIM2s increases mammosphere formation in MCF-7 cells 
 Multiple reports have established that a subpopulation of cells within tumors and 
cell lines is the reservoir of the vast majority of self-renewal and tumorigenic capacities 
possessed by the population as a whole (3, 375-379), and have termed these cells cancer 
stem cells or tumor-initiating cells. The SLUG oncogene, which we have previously 
shown to be a direct target of SIM2s in breast cancer cells (Fig. 13), has been shown to 
play a role in DNA damage responses and the biology of normal and transformed stem 
cells (114, 124, 277-280, 380). Therefore, we assessed in vitro self-renewal activity and 
DNA damage signaling in SCR and SIM2i MCF-7 cells. When plated under ultra-low 
attachment conditions in standard growth media, SIM2i MCF-7 cells had a 6-fold greater 
rate of mammosphere formation (Fig. 15), suggesting that depletion of SIM2s resulted in 
enhanced self-renewal capacity. However, when plated in serum free media 
supplemented with EGF and bFGF, there was no significant advantage for either cell line 
(not shown). This may indicate that loss of SIM2 did not increase self-renewal capacity 
per se, but conferred resistantance to the pro-differentiation effects of serum.  
Alternatively, the mammosphere forming population in the SCR MCF-7 line may be 
more growth factor-dependent than their counterparts in the SIM2i cells, which is masked 
by excess growth factors in the media.   
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Several reports suggest that expression of CD24, in combination with either CD29 or 
CD44, can be used in FACS experiments to sort out stem cell-like tumor initiating cells 
in MCF-7 cells (270, 381, 382), which are generally CD24lo and CD29 or CD44 positive.  
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 Comparison of these markers in SCR and SIM2i MCF-7 revealed that nearly all 
SCR MCF-7 cells were CD24+ CD44+, and the putative tumor-initiating cell enriched 
CD24low CD44+ population comprised approximately 5% of the total population, 
consistent with previous results from other laboratories (Fig. 16). SIM2i cells had largely 
ceased to express CD44, consistent with an EMT (Fig. 16).  CD24 expression was also 
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greatly reduced, but a significant population of CD24low cells could still be observed 
(Fig. 16). These results were difficult to interpret due to the complete loss of CD44 in the 
SIM2i cells, so we performed a similar experiment using antibodies to CD24 and CD29. 
As shown in Fig 16, the SCR cells were largely double positive for the markers assayed, 
but contained a CD24low CD29+ subpopulation which accounted for approximately 5% 
of the cells.  The majority of SIM2i MCF-7 cells were also CD29+, but only a small 
fraction were CD24+, and these expressed low amounts of CD24 (Fig. 16). There 
appeared to greater numbers of CD24low CD29+ cells in the SIM2i cells, suggesting that 
they contained more tumor-initiating cells, which is consistent with their greater 
tumorgenicity (Fig. 16 and 8). It has been observed that treatments with ionizing 
radiation can enrich for stem-like cells, which are more resistant to cellular stress and 
DNA damage (278, 381). In order to determine if the expanded CD24low CD29+ 
population in the SIM2i MCF-7 cells could be stem-cell like, we analyzed sham exposed  
and 10Gy - exposed cells for expression of CD24 and CD29.  As expected, treatment 
with ionizing radiation enriched for CD24low CD29+ cells, suggesting that expansion of 
this cell type in the SIM2i MCF-7 cells may explain their greater tumorgenicity and in 
vitro self-renewal (Fig. 17).  
 
4.2 Loss of SIM2s increases DNA damage resistance and alters DNA damage 
responses 
Expression of slug and stem cell-like behavior are associated with drug resistance, 
and therefore we expected that SIM2i MCF-7 cells would be more resistant to DNA  
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damaging agents than their SCR counterparts. As expected, SIM2i MCF-7 cells 
were resistant to the anthrcycline radiomimetic doxorubicin (Fig. 18A). However, the 
SIM2i MCF-7 cells were at least as sensitive to ionizing radiation as the SCR cells (Fig. 
18A), raising the possibility that the resistance to doxorubicin was due to stem cell 
associated drug pumps (383). 
 
 
 
 
 In order to test this, we performed immunofluorescent staining of gH2AX foci, 
which localized to sites of DNA damage under repair. Both SCR and SIM2i MCF-7 cells 
had numerous gH2AX foci after doxorubicin treatment, and there was no observable  
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Figure 21, Continued. 
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difference the number of foci or repair kinetics (Fig. 18B and not shown), indicating that 
the SIM2i MCF-7 cells resistance to doxorubicin was unlikely to be due to enhanced drug 
efflux. MCF-7 cells have a functional p53 response that closely resembles that found in 
tumors with wild-type p53 (384).   
 
To ensure that the differences in survival were not due to alterations in p53 status, 
we performed western blot analysis of p53 and sequenced the p53 mRNA in SCR and 
SIM2i MCF-7 cells. Sequence analysis revealed no mutations in the mRNA. However, 
we observed that p53 levels in the SIM2i MCF-7 cells were dramatically higher than in 
the SCR cells, in the absence of any stress treatment (Fig. 19A and 19B). This caused us 
to ask how p53 target gene expression was affected in SCR and SIM2i MCF-7 cells. The 
majority of p53 target proteins such as NOXA and MDM2 were induced normally by 
ionizing radiation and doxorubicin, with most genes induced more rapidly by ionizing 
radiation (Fig. 19A and 19B). However, p21 and the pro-apoptotic protein NOXA were 
not induced by either treatment in the absence of SIM2 (Fig. 19A and 19B). 
Immunofluoerescence analysis confirmed that even in cells that had sustained massive 
DNA damage as measured by formation of H2AX repair foci, p21 was uninducible in 
SIM2i MCF-7 cells (Fig. 19C). Analysis of p53 target gene mRNA expression suggested 
that the defect in induction of p21 was at the level of transcription, while the effect on 
NOXA was unclear (Fig. 20).Other p53 targets such as MDM2 were induced normally in 
the absence of SIM2 (Fig. 20), suggesting that SIM2 may be a promoter-specific p53 co-
regulator. ChIP experiments confirmed that SIM2s binds to the p21 promoter after 
doxorubicin treatment (R. Metz, unpublished observations), raising the possibility that 
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transcriptional complexes containing SIM2 and p53 regulate p21 expression. To begin to 
address this, we asked if SIM2 is inducible by DNA damage and performed co-
immunoprecipitation experiments with p53 and SIM2. We found that SIM2 is not 
induced by DNA damage at the RNA level (not shown). 
1uM Doxorubicin
SIM2
2hr 4hr 8hr 24hr
β−Actin
2hr 4hr 8hr 24hr
10 Gy IR
Time after treatment :
Blot: m @ hp53
IP:
IgG IgG
P53
(gt)
P53
(gt)
SIM2
(Rb)
SIM2
(Rb)
Untreated 1uM Dox 8HrB
A
Figure 22. DNA damage triggers stabilization of SIM2 and interaction with p53 complexes. (A) Western blot analysis of SIM2 
expression  at the indicated times after treatment with either Doxorubicin or ionizing radiation. (B) Co-immunoprecipitation of 
SIM2 and p53. Antibodies used for IP are indicated above lanes. IP samples were blotted with anti-p53 antibody.  
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Intriguingly, SIM2 protein levels were robustly increased by both ionizing 
radiation and by doxorubicin (Fig. 22A), and as SIM2 is regulated by ubiquitin ligases 
(385, 386), this data suggests a stabilization mechanism similar to those known to 
mediate p53 and HIF1α responses (387-391). Additionally, we found that SIM2 and p53 
appear to interact after treatment with DNA damaging agents (Fig. 22B), leading to 
hypothesize that SIM2 is a promoter-specific co-regulator of p53 target genes during 
DNA damage response signaling. These studies demonstrate that the molecular basis of 
tumor suppression by SIM2s is highly complex and multi-facetted, involving at least 3 
distinct pathways: MMPs, EMT, and DNA damage response. 
  78
CHAPTER V 
CONCLUSIONS 
 
5.1 SIM2 is a transcriptional barrier to EMT 
 
 EMT has been studied in the context of development for several decades. 
However, only recently has the relevance of EMT to carcinogenesis and metastasis 
become widely accepted. Despite the rarity of full-blown EMT in human tumors, 
hundreds of published articles have identified dozens of transcription factors that initiate 
or promote EMT. Many of these factors such as twist, slug, and snail have been shown to 
be oncogenic in vivo, despite a lack of association in tumors with the clear EMTs they 
elicit in some contexts in vitro. The majority of studies on EMT involve ectopic 
expression techniques that raise the expression levels of these factors to hundreds or 
thousands of times beyond physiologic levels, which taken together with data from tumor 
samples suggests that a relatively high threshold of pro-EMT signalling must be reached 
before a clear phenotypic change results. This implies the existence of multiple factors 
that coordinately oppose EMT, though these factors have received little attention 
compared to pro-EMT pathways and transcription factors. In this study, we demonstrated 
that loss of SIM2 promotes EMT-like changes in vivo and in vitro (Fig. 8 and Fig.13). 
SIM2 is to our knowledge the first factor shown to repress the SLUG oncogene, and with 
the exception of work showing that estrogen signaling suppresses Snail expression via 
MTA3 (246), the first to elucidate a factor that opposes EMT at the level of transcription. 
SIM2 has been shown previously to stifle xenobiotic and hypoxia-driven gene expression 
(329, 330), suggesting that SIM2 stands astride and stifles several paths to EMT. Loss of 
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SIM2 was insufficient to stimulate EMT in non-transformed MCF-10A cells (Fig. 15), 
implying that multiple redundant factors block EMT in mature tissues and that these 
factors tend to be lost during transformation, whether the tumor cells display EMT-like 
features or not. SIM2-/- mammary glands displayed some features of EMT such as loss 
of E-cadherin, overexpression of slug, and nuclear accumulation of β-catenin (Fig.13). 
This apparent discrepancy between the untransformed cells in the gland and the MCF-
10A cells which did not undergo EMT may be explained by the difference in 
effectiveness between a gene knockout and shRNA-mediated silencing. If SIM2 were to 
be fully deleted in MCF-10A cells, it is possible that the anti-EMT barrier would be 
lowered sufficiently to allow for EMT to occur.  
 
 EMT is central to developmental processes in the early embryo and structural 
assembly of tissues such as the heart, palate, muscle, and bone (392, 393), although 
uncontrolled EMT can lead to defects due to mesenchymal hyperplasia (297). 
Development of many tissues such as the kidneys also requires MET, which suggests a 
critical role for proteins that restrict EMT.  Defects in palate fusion, diaphragm 
development, and bone formation in Sim2-/- mice imply that SIM2-mediated cessation of 
EMT is crucial for development of multiple tissues (337).  Considering that EMT-like 
changes tend to occur in advanced tumors and EMT-promoting factors are tumor-
promoting without regard to EMT, strategies aimed at re-establishing expression of SIM2 
or other barriers to EMT identified in the future have great therapeutic potential. 
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5.2 SIM2 has important tumor suppressor function independent of slug regulation 
 
 Previously, MMP3 was identified as a direct target of SIM2-mediated repression 
(336). In this study, we showed that SIM2 represses MMP2 at the expression and 
activation levels. Both MMP2 and MMP3 are associated with poor outcomes multiple 
tumor types, with one of the consistent associations being MMP2 and poor outcome in 
breast tumors (394-400). MMP2 is associated with metastasis, angiogenesis, tumor grade, 
size, and relapse free survival (401-403), consistent with the rapid metastasis and large 
vascular tumors formed by SIM2i MCF-7 cells in our study (Fig. 9). While the 
mechanism by which SIM2s represses MMP2 is unclear, we hypothesize it involves 
direct binding and repression of the MMP2 promoter. How SIM2 loss resulted in MMP2 
activation is likely to be more complicated and indirect. NF-κB has been reported to 
promote MMP2 activation via induction of MMP14, which processes the MMP2 
proenzyme (404, 405). Additionally, preliminary results suggest that SIM2 can 
antagonize NF-κB in some cases (T. Gustafson and R. Metz, unpublished observations), 
and MMP14 expression is elevated in SIM2i MCF-7 cells (Fig. 12), suggesting that this 
pathway may explain the effect of SIM2 on MMP2 activation. These results strongly 
suggest that SIM2 has multiple oncogenic targets and provide a rationale for therapeutic 
strategies based on re-establishing SIM2 expression in tumors without EMT-like features. 
 
 
5.3 p53 responses are modulated by SIM2 
 
 We show in this study that SIM2 modulates p53 signaling directly through target 
genes such as p21, and likely indirectly through regulation of slug (Fig. 13). As p53 is 
central to DNA damage responses and suppression of tumorigenesis in virtually every, if 
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not all tissues, this implies that SIM2 is crucial for tumor suppression in a variety of 
tissues. By co-regulating genes such as p21 and PUMA, and through suppressing slug, 
SIM2 may function to fine tune the output of p53 activation, which can lead either to cell 
cycle arrest or apoptosis. Given the tumor suppressive potency of p53 and the frequency 
with which it is deleted or mutated in human cancers, it seems possible that those tumors 
with no overt defects in p53 itself may have found other ways to neutralize p53 pathway 
output, that is, all tumors are to one degree or another aberrant in p53 signaling. SIM2, as 
a promoter-specific modulator of p53 function, may represent a path for evasion of p53. 
It is noteworthy that the p53 targets whose transcription is apparently promoted by SIM2 
are generally tumor suppressive (p21, PUMA), while some of those unaffected are 
oncogenic (MDM2). SIM2 loss may even in some cases act as a gain-of function p53 
mutation, and allow hijacking of p53 signaling to benefit the tumor, which can 
differentially effect treatment response (406). As SIM2i cells displayed altered responses 
to ionizing radiation and the radiomimetic doxorubicin (Fig. 16), SIM2 may therefore 
have value not only as a prognostic indicator, but assist in selection of appropriate 
therapies. 
 
 
5.4 Implications of SIM2 loss in breast cancer 
 Given the known oncongenic potency of the SIM2 target genes SLUG and 
MMP2, we hypothesize that SIM2 loss associates with poor prognosis in breast cancer. 
Slug and MMP2 promote angiogenesis, metastasis, and recurrence, suggesting that loss 
of SIM2 would also be associated with these processes. SIM2s-mediated antagonism of 
HIF1α is another factor that could influence the effect of SIM2 loss in breast tumors. In 
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addition to promoting EMT, angiogenesis and metastasis, hypoxia interfaces with p53 
signaling in the presence and absence of DNA damage, resulting in unique gene 
expression patterns in each case (407). It is possible that SIM2 loss could act as a hypoxia 
mimetic, or simply compound the hypoxia that is found in even the smallest tumors 
(301). SIM2 is also likely to function in the interface between hypoxia and p53, and play 
a role in the cell's decision to survive and initiate angiogenesis or undergo apoptosis.  
 
 We also demonstrated that loss of SIM2 increased self-renewal and putative stem-
cell-like tumor initiating cell populations in MCF-7 cells (Fig. 15). These cells are 
thought to be the root of tumor recurrence, and to play roles in angiogenesis(1). This 
implies that SIM2 promotes differentiation, and that reestablishment of SIM2 expression 
would synergize with many treatments in use and under investigation. This is supported 
by the ability of Singleminded proteins to promote differentiation of isotocin cells, CNS 
midline cells, and possibly TRH and somatostatin-secreting neurons (408-410). The 
potential role of SIM2 in suppression of stem cell identity will require in vivo validation, 
and studies underway to generate a conditional SIM2 allele that will clarify this issue. 
 
5.5 SIM2 and basal-like breast carcinoma 
 Basal-like carcinomas are associated with poor prognosis, EMT, recurrence, drug 
resistance, aggressive clinical course, and are hypothesized to contain greater numbers of 
tumor-initiating cells (108, 110, 117, 121). Recently, it was reported that the basal 
phenotype is regulated by slug and hypoxia (114), suggesting that loss of SIM2 might 
also form part of the molecular definition of basal-like tumors via permission of slug 
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expression and HIF1α activity. Consistent with this theory, SIM2 is not expressed in 
basal / myoepithelial cells in the mouse mammary gland, indicating its expression may 
suppress basal identity, or that basal-like carcinomas arise from cells that do not express 
SIM2. SIM2 loss is not likely to be sufficient to permit manifestation of the basal 
phenotype, as SIM2 is lost or reduced in up to 70% of tumors while basal-like 
carcinomas comprise less than 15% of invasive ductal carcinomas (113, 336). Whether 
SIM2 loss promotes the basal phenotype or basal carcinomas arise from cells without 
SIM2, SIM2 is a potential diagnostic marker to distinguish basal-like carcinomas. 
 
 
5.6 SIM2 and Down syndrome 
 Individuals with DS have a spectrum of health disorders that is significantly 
different from the general population. In addition to differential risk for development of 
many cancers, DS patients have increased incidence of palatal abnormalities and 
atrioventricular (AV) septum defects, all of which involve EMT or genes that control 
EMT (136, 137, 151, 411). DS patients have greatly increased risk for development of 
leukemias, but we are unable to detect SIM2 in white blood cells and believe SIM2 does 
not play a role in DS-related leukemias. We hypothesize that regulation of EMT and 
tissue remodeling factors by SIM2 contributes both to the physical abnormalities and 
unique solid tumor protection experienced by DS patients. 
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5.7 Proposed model of SIM2 function in epithelia 
 
  
 
 
 
Our results in mouse mammary epithelium and breast cancer cells suggest the 
function of SIM2 in mature tissue is to preserve epithelial identity within individual cells 
and in the tissue as a whole (Fig. 23), and does so along 3 main paths: Suppression of 
slug and possibly other EMT-promoting factors, maintenance of tissue integrity by 
suppression of MMPs, and by ensuring an appropriate response to DNA damage. We 
hypothesize that SIM2 expression is low under normal conditions, perhaps via E3 
ubiquitin ligase-mediated degradation. Upon a challenge such as hypoxia or DNA 
Figure 23. The role of SIM2 in breast epithelium. In normal cells, SIM2 contributes to maintenance of differentation by suppressing 
slug, thereby preserving expression of epithelial genes such as E-cadherin and keratin 18. SIM2 may also actively promote 
differentiation by this mechanism, though  it is not known at which point during differentiation of mammary stem cells SIM2 
expression commences. In tumor cells, SIM2 exerts similar pro-differentiation effects and its loss leads to progression. Via 
regulation of MMPs and slug, SIM2 inhibits invasion and metastasis 
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damage, SIM2 is rapidly stabilized, perhaps under the control of DNA-damage activated 
kinases such as CHK1. SIM2 would then suppress genes that might perturb the 
epithelium such as slug, while promoting cell cycle arrest via p21, thereby maintaining 
the tissue. As progenitor cells rely upon slug for protection from radiation-induced death 
(124, 278), SIM2 may be an important difference between the DNA damage responses of 
stem cells and differentiated cells. This also suggests that lack of SIM2 might be a useful 
stem cell marker, as based upon its apparently pro-differentiation effects SIM2 seems 
highly unlikely to be expressed in stem cells, and it is restricted to the epithelial 
compartment where stem cells are thought to reside. While it remains to be elucidated 
whether SIM2 is a cause or effect of differentiation, this study strongly suggests that 
SIM2 has a key role in safeguarding the structural and genomic integrity of epithelial 
tissues. 
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